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ABSTRACT OF DISSERTATION 
Effects of agonistic anti-CD137 antibody on chikungunya virus infection and B cell responses 
By 
Jun Pyu Hong 
Doctor of Philosophy in Biology and Biomedical Sciences 
(Immunology) 
Washington University in St. Louis, 2020 
Professor Michael Diamond, Chair 
 
CD137, a member of the tumor necrosis factor receptor superfamily of cell surface 
proteins, acts as a costimulatory receptor on T cells, natural killer cells, B cell subsets, and some 
dendritic cells. Agonistic anti-CD137 monoclonal antibody (MAb) therapy has been combined 
with other chemotherapeutic agents in human cancer trials. Based on its ability to promote tumor 
clearance, we hypothesized that anti-CD137 MAb might activate immune responses and resolve 
chronic viral infections. We evaluated anti-CD137 MAb therapy in a mouse infection model of 
chikungunya virus (CHIKV), an alphavirus that causes chronic polyarthritis in humans and is 
associated with reservoirs of CHIKV RNA that are not cleared efficiently by adaptive immune 
responses. Analysis of viral tropism revealed that CHIKV RNA was present preferentially in 
splenic B cells and follicular dendritic cells during the persistent phase of infection, and animals 
lacking B cells did not develop persistent CHIKV infection in lymphoid tissue. Anti-CD137 
MAb treatment resulted in T cell-dependent clearance of CHIKV RNA in lymphoid tissue, 
although this effect was not observed in musculoskeletal tissue. The clearance of CHIKV RNA 
from lymphoid tissue by anti-CD137 MAb was associated with reductions in the numbers of 
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germinal center B cells and follicular dendritic cells. Similar results were observed with anti-
CD137 MAb treatment of mice infected with Mayaro virus, a related arthritogenic alphavirus. 
Thus, anti-CD137 MAb treatment promotes resolution of chronic alphavirus infection in 
lymphoid tissues by reducing the numbers of target cells for infection and persistence. 
As a result of agonistic anti-CD137 MAb treatment, antibody responses to multiple T 
cell-dependent antigens including infectious virus, recombinant viral proteins, and conjugated 
haptens but not to a T cell-independent antigen or at homeostasis were impaired. These effects 
were not due to enhanced apoptosis or impaired proliferation of B cells but instead correlated 
with changes in lymphoid follicle structure and GC B cell dispersal, and were mediated by 
CD137 signaling in CD4+ and CD8+ T cells. Our experiments in mice suggest that agonistic anti-
CD137 mAbs used in cancer and autoimmunity therapy may cause GC collapse and impair long-






Chapter 1: Introduction 
Introduction 
Tumor Necrosis Factor Receptor Superfamily 
The members of tumor necrosis factor receptor superfamily (TNFRSF) include proteins with 
extracellular cysteine-rich domains (CRD) and share high-level homology with the archetypical 
member, TNFR1. Most TNFRSFs are expressed in the immune cells, where their signaling plays 
crucial roles in proliferation and protective functions in immune cells in response to pathogens. 
In addition to their role in host defense, the role of TNFRSFs in organogenesis has also been 
identified (Bodmer et al., 2002; Botchkareva et al., 1999; Kong et al., 1999). The extracellular 
CRDs are involved in the formation of disulfide bonds and confer an elongated shape of the 
receptors, which is characterized by a twisted ladder of disulfide bridges (Bodmer et al., 2002). 
The cytoplasmic domains of TNFRSFs function as docking site for signaling adaptor proteins, of 
which two classes exist: TNF receptor-associated factors (TRAF) and “death domain” (DD) 
molecules. The selective binding of signaling adaptors via DD or TRAF binding motif of 
TNFRSFs trigger caspase activation and cell death or NF-κB and other cellular pathways, 
respectively. 
Discovery of CD137 and its ligand 
CD137, also called 4-1BB or TNFRS member 9 (TNFRSF9), is a costimulatory receptor on T 
cells, natural killer cells, B cell subsets, and some dendritic cells. cDNA of CD137 was cloned 
and sequenced in 1989 as an inducible gene from stimulated T cells (Kwon and Weissman, 
1989). Murine CD137 encodes a polypeptide of 256 amino acids (30-kDa glycoprotein). The 
ligand for murine CD137 (CD137L), a 34-kDa type II membrane glycoprotein that has 
homology to TNF, was discovered by constructing soluble forms of CD137 (Goodwin et al., 
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1993). CD137L is highly expressed on mature B and macrophage cell lines, activated B cells and 
dendritic cells (Pollok et al., 1994). CD137L also is inducible in T cells (Goodwin et al., 1993).  
CD137-mediated signaling 
Trimeric forms of CD137L interact with a trimeric form of CD137, facilitating its 
intracellular signaling pathway. The cytoplasmic domain of CD137 associates with TRAF 1, 2 
and 3 at two TRAF-binding consensus sequences (Arch and Thompson, 1998; Jang et al., 1998; 
Saoulli et al., 1998; Ye et al., 1999). Three distinct CD137 signaling pathways have been 
reported: NF-κB-inducing kinase (Jang et al., 1998), p38 mitogen-activated protein kinase 
(Cannons et al., 2000) and c-Jun N-terminal kinase (Cannons et al., 1999). Anti-CD137 
monoclonal antibody (mAb)-mediated crosslinking of cell-surface-expressed CD137 molecules 
triggers internalization into an unidentified endosomal compartment, of which name has been 
proposed to be “CD137 signalosomes,” which could then recruit TRAF molecules (Melero et al., 
2008). 
Immunological consequences of CD137-mediated signaling 
CD137 signaling induced by anti-CD137 mAb enhances proliferation of and interferon (IFN)-γ 
secretion by NK cells in vitro, whereas their cytolytic activity against NK-sensitive tumor cell 
lines remains unchanged, which suggests that anti-CD137 mAb-mediated signaling can 
selectively regulate immune functions of NK cells (Wilcox et al., 2002c). Anti-CD137 mAb-
mediated signaling in activated monocytes increases the expression of TNF-α and IL-8 but 
decreases the expression of IL-10 at transcript level (Kienzle and von Kempis, 2000). CD137-
stimulated monocytes may inhibit antibody responses by promoting B-cell apoptosis (Kienzle 
and von Kempis, 2000). DCs isolated from mice treated with anti-CD137 mAb can better induce 
proliferation of antigen-specific T cells when compared to DCs from mice treated with isotype 
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control mAb (Wilcox et al., 2002a). Anti-CD137 mAb-mediated signaling has been reported to 
promote apoptosis in neutrophils and eosinophils (Heinisch et al., 2001). 
The importance of CD137 signaling in adaptive immune cells has been demonstrated in 
different disease animal models. Anti-CD137 mAb has been shown to enhance proliferation of 
and IFN-γ secretion by CD8+ T cells in acute graft versus host disease (GVHD), cardiac and skin 
allograft rejection, and tumor rejection models (Melero et al., 1997; Shuford et al., 1997). CD137 
stimulation enhances survival of T cells by inducing expression of anti-apoptotic proteins such as 
Bcl-XL (Starck et al., 2005). Anti-CD137 mAb treatment increases CD4+ T cell-mediated GVHD 
(Blazar et al., 2001). CD137 stimulation reportedly abrogates the suppressive activities in Treg, 
although Treg from CD137-/- or WT mice suppress responder T cells to the same extent (Choi et 
al., 2004).  
CD137-deficient mice: the role of CD137 in vivo 
CD137-/- mice show no abnormality in the organs upon gross necropsy or histopathologic 
examination and no abnormality in B cell or T cell development (Kwon et al., 2002). The 
antibody responses to KLH or vesicular stomatitis virus are normal in these mice (Kwon et al., 
2002). In acute viral infection models with some influenza viruses, CD137 signaling is 
dispensable for normal primary responses of CD8+ T cells but is critical for maintenance of 
antigen-specific CD8+ T cells and development of memory CD8+ T cells (Bertram et al., 2002; 
Dawicki and Watts, 2004; Wang et al., 2009). It is worth noting that the CD137 requirement for 
optimal primary CD8+ T cell responses may depend on different models (Wang et al., 2009). In 
contrast to previous reports on a positive costimulatory role of CD137 in CD4+ and CD8+ T cells, 
Lee et. al. show enhanced effector CD4 T cell responses to OVA with adjuvant in CD137-/- mice, 
although antibody responses are comparable to those in WT animals (Lee et al., 2005). 
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Adoptively transferred CD137-/- OT-II cells show early clonal expansion compared to WT OT-II 
cells in WT recipient hosts, and this is not due to intrinsically hyperresponsive properties of 
CD137-/- OT-II cells (Lee et al., 2005). How the lack of CD137 makes CD4+ T cells 
hyperresponsive to a protein antigen in vivo is not clear. It is possible that CD137 may interact 
with another yet unidentified inhibitory ligand, similar to HVEM/LIGHT and HVEM/BTLA 
pairs. Transgenic CD4+ T cells that are adoptively transferred into CD137L-deficient mice show 
minor defects in primary response but significantly impaired recall responses (Dawicki and 
Watts, 2004). CD137-/- mice cannot clear subcutaneously injected RMA-S cells, a NK cell-
dependent MHCI-deficient tumor (Vinay et al., 2004). These mice have reduced numbers of 
spleen and liver NK and NKT cells (Vinay et al., 2004). Increased numbers of conventional DCs 
and plasmacytoid DCs were observed in the spleens of CD137-/- mice, compared to WT animals. 
CD137 may negatively regulate myelopoiesis by interacting with CD137L on myeloid 
progenitors and regulating their proliferation (Kwon et al., 2002; Lee et al., 2008). Moreover, 
CD137 may be required for M cell functional maturation in nasopharyngeal associated lymphoid 
tissue and Peyer’s patch epithelium (Hsieh et al., 2010). 
Anti-CD137 antibody as immunotherapy for cancer 
CD137-mediated signaling is an intense focus of cancer therapy research. Although I focus on 
agonistic anti-CD137 mAb here, one of the active areas of research is also on chimeric antigen 
receptor (CAR) T cells, which are autologous T cells genetically modified to express CARs that 
consist of antigen-binding domain fused to transmembrane, costimulatory, and CD3ζ domains. 
One of the largest, promising CAR classes includes CD137 costimulatory domain (Li et al., 
2018). The efficacy of anti-CD137 mAb as immunotherapy for cancer is studied as a 
monotherapy or a combined treatment with other antibodies and/or reagents.  
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As a monotherapy, anti-CD137 mAb shows efficacy in the murine models of 
hepatocellular carcinoma, lymphoma, some melanoma, thymoma, and lung, breast and prostate 
carcinoma (Fisher et al., 2012; Gauttier et al., 2014; Houot et al., 2009; Morales-Kastresana et 
al., 2013a; Narazaki et al., 2010; Shi and Siemann, 2006). The lymph node biopsies from 
untreated lymphoma patients show significant percentages of CD137-expressing cells among 
tumor-infiltrating T cells, suggesting that the target of anti-CD137 mAb is selectively expressed 
on cells with potential anti-tumor activities (Houot et al., 2009). The anti-CD137 mAb-mediated 
tumoricidal activities are mediated by NK cells and effector and memory CD8+ T cells and may 
involve local reductions of myeloid-derived suppressor cells and Tregs in tumor 
microenvironments (Gauttier et al., 2014; Houot et al., 2009; Narazaki et al., 2010). In mice 
injected with EG7 lymphoma cells, both the perforin/granzyme and FasL play important roles in 
tumor rejection following anti-CD137 mAb treatment (Morales-Kastresana et al., 2013b). 
However, anti-CD137 mAb treatment has a minimal effect on poorly immunogenic tumor cells 
(Curran et al., 2011; Wei et al., 2013; Westwood et al., 2014). 
Several therapies are being investigated combining anti-CD137 mAb with other 
immunomodulatory antibodies, tumor-targeting antibodies and/or non-antibody reagents that 
enhance cancer immunity. Immunomodulatory antibodies including anti-PD-1, anti-CTLA-4, 
anti-PD-L1, anti-OX40, anti-CD40, anti-TIM-3, and anti-CD4 mAb in combination with anti-
CD137 mAb show at least some synergistic efficacy (Choi et al., 2007; Guo et al., 2013; Kocak 
et al., 2006; Morales-Kastresana et al., 2013b; Palazon et al., 2012; Wei et al., 2013; Westwood 
et al., 2014). Of note, not all combined treatments show synergistic efficacy. The therapeutic 
efficacy of anti-CD137 mAb is abrogated by anti-PD-1 mAbs in a spontaneous lymphoma model 
(McKee et al., 2017). Tumor-targeting antibodies that are being studied in combination with anti-
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CD137 mAb include anti-epidermal growth factor receptor (cetuximab), anti-HER2 
(trastuzumab), and anti-CD20 (rituximab) mAbs (Kohrt et al., 2014; Kohrt et al., 2011; Stagg et 
al., 2011). Rituximab coated on the lymphoma cells increases the expression of CD137 on NK 
cells, and subsequent stimulation of CD137 with targeting mAb enhances rituximab-dependent 
cytotoxicity against the tumor cells (Kohrt et al., 2011). Combinations of anti-CD137 mAb with 
different immunization strategies are also being investigated. Anti-CD137 mAb combined with 
tumor lysate-pulsed DC vaccine, hybrids of DC and syngeneic endothelial cells, irradiated tumor 
cells secreting granulocyte-macrophage colony-stimulating factor, irradiated tumor cells 
expressing fms-related tyrosine kinase 3 ligand (FVAX), or tumor cells expressing single-chain 
variable fragment against Herpes virus entry mediator receptor on the cell surface synergistically 
enhanced tumor regression (Curran et al., 2013; Ito et al., 2004; Ko et al., 2007; Park et al., 
2012). In mice that are therapeutically vaccinated with FVAX, anti-CD137 mAb treatment 
enhances tumor rejection and elicits strong infiltration of KLRG1-expressing CD4+ and CD8+ T 
cells with a novel phenotype characterized by enhanced, multipotent cytotoxicity and driven by 
the T-box transcription factor Eomesodermin (Curran et al., 2013; Curran et al., 2011). Other 
strategies include combinations with proto-oncogen B-Raf inhibitor, IL-12 gene therapy, or 
oncolytic virus (John et al., 2012; Knight et al., 2013; Xu et al., 2004). 
Chikungunya virus  
Epidemiology and pathogenesis 
Chikungunya virus (CHIKV) is a re-emerging, enveloped Alphavirus in the Togaviridae family 
of positive (+) sense RNA viruses and is transmitted by Aedes species mosquitoes. Since the first 
isolation of CHIKV in Tanzania in 1952 and subsequent outbreaks throughout Africa, India, 
Southeast Asia and Polynesia (Robinson, 1955; Staples et al., 2009), CHIKV emerged in the 
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Caribbean in 2013 and has spread throughout Central and South America, affecting more than 
1.7 million people (Petersen and Powers, 2016). The symptoms of CHIKV infection include 
fever, rash, malaise, myalgia and polyarthritis (Simon et al., 2011). Although symptoms can 
resolve within a few weeks, 30% to 60% of individuals report persistent musculoskeletal pain 
months to years after initial diagnosis (Rodriguez-Morales et al., 2015; Rodriguez-Morales et al., 
2016; Sissoko et al., 2009). Debilitating chronic arthralgia caused by CHIKV infection can result 
in a stooped and contorted posture, for which “chikungunya” is named in Makonde language.  
One of the prospective cohort studies addresses the pathogenesis of CHIKV infection in 
49 hospitalized patients from Reunion Island, who are followed from the first day of clinical 
acute infection until 12 months after infection (Hoarau et al., 2010). Both groups of individuals 
that eventually recover from acute infection and those who experience chronic relapsing 
arthralgia 12 months after infection show a strong immune response as demonstrated by a robust 
activation of DC, NK, CD4+ and CD8+ T cells but relatively weak Th1/Th2 cytokine responses 
during the acute phase of infection. However, only the individuals with chronic symptoms show 
increased levels of IFN-α mRNA and IL-12 in peripheral blood mononuclear cells (PBMC) and 
serum, respectively, for months compared to the individuals who recover. CHIKV RNA and 
protein have been detected in perivascular synovial macrophages in one chronic patient at 18 
months after infection (Hoarau et al., 2010). Persistent viral RNA in cells may act as a pathogen-
associated molecular pattern (PAMP) and contribute to CHIKV-induced inflammation and 
arthritis (Magnusson et al., 2006; McCarthy and Morrison, 2017; Zare et al., 2004). 
Murine model of chikungunya virus pathogenesis 
The most commonly used experimental animal models of CHIKV are mice and nonhuman 
primates. Here, I introduce only the murine model, but both the murine and nonhuman primate 
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models have their advantages for studying different aspects of CHIKV infection. Due to a lack of 
functional conservation between some mouse and human genes, there are cases where murine 
models do not fully recapitulate key aspects of human CHIKV disease such as maternal/neonatal 
transmission, enhanced CHIKV disease in elderly individuals and chronic disease pathogenesis. 
There are three different murine models of CHIKV: lethal neonatal challenge model, 
immunocompromised model of lethal disease and CHIKV arthritis/myositis model. Here, I use 
the third model and describe it in more details. 
Tropism of chikungunya virus 
In murine model of CHIKV, mice are inoculated subcutaneously in the footpad. During the acute 
phase of infection, CHIKV is readily detected in skeletal muscle cells, synovial fibroblasts, other 
nonhematopoietic and hemaotopoietic cells in mice (Hawman et al., 2013; Nair et al., 2017; 
Young et al., 2019). During the chronic phase, the reservoir of CHIKV in muscle and joint 
tissues is less clear, although experiments with a Cre recombinase CHIKV strain and reporter 
mice showed that fibroblasts and skeletal muscle cells harbored persistent viral RNA (Young et 
al., 2019). Even after infectious virus is cleared from the blood and within tissues, as judged by 
plaque- or focus-forming assays, CHIKV RNA can be detected in the ipsilateral and contralateral 
ankles of WT mice for at least 16 weeks after infection and in the spleens for 6 weeks after 
infection, as judged by quantitative reverse transcription-PCR (qRT-PCR) (Hawman et al., 
2013). Viral tropism in lymphoid tissues is not clearly defined, although macrophages and 
monocytes are a reported reservoir of chronic CHIKV infection in mice and nonhuman primates 
(Labadie et al., 2010). 
Immune responses and chikungunya virus pathogenesis in mice 
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CHIKV-infected mice exhibit a biphasic pattern of footpad swelling in the ipsilateral feet. The 
first peak of swelling occurs between 2 and 3 days post-infection (dpi) and is smaller than the 
second, which occurs between 6 and 7 dpi. The first peak is due to extensive viral replication in 
the footpad, resulting in cytokine production, tissue edema and some cellular infiltrates. Pattern 
recognition receptors (PRR) that recognize PAMPs induce type I IFN responses, which are 
necessary to prevent lethality (Couderc et al., 2008; Schilte et al., 2012). Signaling via PRRs and 
IFN receptors promotes secretion of pro-inflammatory cytokines, which recruit innate and 
adaptive immune cells to the site of infection. Macrophages and inflammatory monocytes may 
have both protective and pathogenic roles in CHIKV disease. Depletion of macrophages using 
clodronate treatment reduces foot swelling (Gardner et al., 2010), while CCR2-/- mice, which 
lack monocyte/macrophage infiltration, show enhanced foot swelling and neutrophil-dominated 
inflammation (Poo et al., 2014a). Depletion of macrophages also increases viremia, suggesting 
that macrophages promote inflammation while aiding in clearance of virus (Gardner et al., 2010). 
In mutant mice lacking γδ T cells, which are the most abundant T lymphocytes in the skin and 
mucosal surfaces, increased numbers of infiltrating inflammatory monocytes at the site of 
CHIKV infection exacerbate foot swelling and tissue damage (Long et al., 2016). Replication of 
CHKV in bone reportedly causes osteoclastogenesis and bone loss (Chen et al., 2015). 
 The second peak of foot swelling is driven by immune-mediated responses and damage 
associated with the influx of inflammatory cells into the joint and surrounding tissue. Antibody 
responses are critical in controlling CHIKV infection (Hawman et al., 2016; Hawman et al., 
2013; Poo et al., 2014b). Genetic or acquired deficiency of CD4+ T cells or MHC class II 
molecules result in reduced foot swelling without significant effect on viremia (Poo et al., 2014b; 
Teo et al., 2013). In contrast, genetic or acquired deficiency of CD8+ T cells did not affect foot 
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swelling or viremia (Teo et al., 2013). The minimal role that CD8+ T cells seem to have during 
CHIKV infection warrants further studies. CHIKV-neutralizing antibodies protect mice from 
persistent viremia and exacerbated inflammation in the feet, as demonstrated by B cell-deficient 
mice and adoptive transfer of exogenous CHIKV-neutralizing antibodies to Rag1-/- mice 
(Hawman et al., 2013; Poo et al., 2014b). 
B cell response 
Depending on the nature of antigens, either T-dependent (TD) or T-independent (TI) B cell 
response can occur. Antigens of low valency trigger initial cell cycle progression in activated B 
cells, which then rapidly proliferate in response to cognate T cell-derived signals. For certain 
antigens, strong signaling via co-receptors such as toll-like receptors (TI type I response) or high 
degree of multivalency of antigens (TI type II response) can overcome the need for T cell help 
and result in cell division and subsequent differentiation. 
Germinal center reaction 
During TD B cell response, encounter of antigen-engaged B cells with cognate T cells is 
facilitated by upregulation of CCR7 and EBI2 and downregulation of S1PR1 on the B cells and 
their migration to the interface of the B cell follicle and the T cell zone (Cyster et al., 2014). 
After T cell help initiates germinal center (GC) formation, the maintenance of GC is regulated by 
ongoing B-T interactions via ICOSL/ICOS, CD40/CD40L, SLAM and PD-L1/PD-1 (Cannons et 
al., 2011; Shi et al., 2018). GCs in lymphoid tissues are complex anatomical sites where somatic 
hypermutation (SHM) and antibody isotype switching, or class-switch recombination (CSR), 
occurs. GC B cells proliferate extensively and traffic through the light and dark zones as part of 
an antigen-driven affinity-based clonal selection process (reviewed in (Mesin et al., 2016)). In 
the light zone, GC B cells recognize cognate antigens and undergo selection with the cytokine-
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directed input of follicular helper T cells (Tfh), which themselves are modulated by follicular 
regulatory T cells (Tfr) (Linterman et al., 2011). GC B cell confinement is mediated by the 
migration inhibitory receptors S1PR2 and P2RY8 (in human), which signal through 
heterotrimeric G-proteins containing Gα13 (Muppidi et al., 2014). S1PR2 is uniquely expressed 
by GC B cells and controls the size of chronic GCs (Green et al., 2011). The ligand for S1PR2 
and four other S1PRs is sphingosine-1-phosphate (S1P), which is a metabolic intermediate made 
by all eukaryotic cell types during sphingolipid metabolism aided by the action of sphingosine 
kinase 1 and 2 and secreted by some cell type (Schwab and Cyster, 2007). The GC confinement 
of Tfh may also be mediated by S1PR2 and further augmented by their CXCR5 expression 
(Moriyama et al., 2014). Early localization of activated T cells at the interface of the B cell-
follicle and T zone is guided by EBI2 on T cells, similar to the role of EBI2 on early-activated B 
cells (Li et al., 2016). Production of its ligand 7α,25-dihydroxycholesterol (7α,25-OHC) by 
CH25H and CYP7B1 in lymphoid stromal cells may be important to establish 7α,25-OHC 
gradient required for B cell responses (Yi et al., 2012). EBI2 on T cells guides their localization 
near CD25-expressing DCs, which may promote distinct cell fate decisions dependent on IL-2 
availability (Li et al., 2016). GC B cells without strong affinity for antigens or without T cell 
help undergo apoptosis. CD40-mediated signaling not only is important for GC maintenance but 
also influences the fate decisions of GC B cells. The GC reaction culminates in the generation of 
memory B cells and plasma cells, the latter of which are professional antibody-secreting cells. 
Some memory B cells and early short-lived plasma cells develop independently of GC (Nutt et 
al., 2015; Toyama et al., 2002). 
Fate decisions in germinal center 
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Although the exact mechanism of GC B cell fate decisions is not clear, the strength of CD40-
mediated signaling seems to be an important factor; the strong CD40 signal leads to plasma cell 
differentiation, while the weaker CD40 signal leads to memory B cell differentiation or recycling 
GC cell fate (Ise et al., 2018; Koike et al., 2019). The B cells expressing higher-affinity B cell 
receptor (BCR) can acquire greater amount of antigen for presentation to Tfh (Victora et al., 
2010). Thus, high-affinity GC B cells with greater extent of affinity maturation are selected into 
the plasma cell compartment, while memory B cell differentiation has more permissive affinity 
requirements (Phan et al., 2006; Smith et al., 1997). IL-4 and IL-21 secreted by Tfh promote B 
cell proliferation, CSR, and differentiation into plasma cells or GC B cells (Moens and Tangye, 
2014; Vinuesa et al., 2016). BCR signal by engagement of antigens presented by follicular 
dendritic cells (FDC) as well as CD40 and cytokine receptor signal are integrated in GC B cells 
to influence their fate decisions, and these signaling pathways seem to be rewired in GC B cells 
(Luo et al., 2018). It is possible that a small difference in CD40 signal as determined by the 
extent of T cell contact results in both quantitative and qualitative difference in signaling in GC 
B cells.  
 Transcription factors define the identity of a particular cell population. A sequential 
transition from one stage of cell differentiation state to another, e.g. from naïve B cells to plasma 
cells, is induced by dynamic regulation of transcription factors. In B cells, Pax5 and Blimp-1 
mutually repress each other, forming a double-negative feedback loop, or a toggle switch-like 
gene regulatory network (Gardner et al., 2000). Pax5 defines B-cell identity from early 
progenitor B cells to mature B cells. However, expression of almost half of the genes induced by 
Pax5 is absent or reduced in plasma cells, which do not express Pax5 (Schebesta et al., 2007). 
Instead, expression of Blimp-1 and Irf4 is increased, which promotes plasma cell status. The 
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transcriptional program of GC B cells is regulated by their master transcription factor Bcl6. 
Transcription factors involved in development, activation, maturation, and differentiation of B 
cells, such as NF-κB, Irf4, Mef2c, Myc, E2A, Ebf1, Obf-1, and Bach2, as well as a Rho-Rac 
guanine-exchange factor Dock8 are critical in GC initiation and/or maintenance (De Silva and 
Klein, 2015). Particularly, Bach2, which is downstream of Pax5, can interact with Bcl6 and 
repress Blimp-1 expression and plasma cell differentiation (Ochiai et al., 2008). SHM is 
compromised in Bcl6-/- mice, but class-switched memory B cells can still form in these animals 
in the absence of germinal centers (Toyama et al., 2002). However, both SHM and CSR are 
abrogated in Bach2-/- mice, raising the question on the role of Bach2 for CSR (Muto et al., 2004). 
A delay-driven diversity model has been proposed, postulating that Bach2 achieves a time delay 
in Blimp-1 induction, which inhibits plasma cell differentiation while allowing induction of AID 
by Pax5 and, therefore, CSR (Muto et al., 2010).  
Marginal zone B cells 
Lymphoid tissues contain follicular B cells and marginal zone (MZ) B cells, the latter of which 
express polyreactive BCR, produce natural IgM and IgG antibodies, and protect against blood-
borne bacterial infection in a T cell-independent manner (Cerutti et al., 2013; Tanigaki et al., 
2002). Several studies have provided some insights into follicular versus MZ B cell fate decision. 
Transitional T1 B cells enter the spleen and further mature into AA4.1+, recirculating T2 B cells, 
which express high levels of IgD and CD23 and intermediate levels of CD21 (Allman et al., 
2001). Initially dependent only on tonic BCR signals via self-antigens for survival, transitional B 
cells eventually require both tonic BCR signals and BAFF-mediated survival signals (Cancro, 
2009). BAFFR can activate both the canonical and non-canonical NF-κB pathways (Siebenlist et 
al., 2005). The non-canonical NF-κB pathways through IKKα-mediated targeting of p100 for 
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cleavage to produce p52, or NF-κB2, support B-cell survival functions mediated by BAFF from 
transitional to mature B cell stage (Senftleben et al., 2001). In addition to the non-canonical NF-
κB pathways, the development of MZ B cells, but not follicular B cells, requires the canonical 
NF-κB pathways through p50, which can complex with both c-Rel and RelA in B cells (Cariappa 
et al., 2000). MZ B cells also require the signals mediated by Notch through its ligand DL1, 
which is expressed mainly on the luminal face of venules in the red pulp of the spleen and some 
in the marginal zone (Tan et al., 2009). Based on some experiments involving mice with the 
mutations in or the lack of molecules regulating BCR signaling such as Aiolos, Btk, CD21, 
CD22 or Igα, the strength of BCR signaling may influence MZ versus follicular B cell 
development, with weak BCR signaling inducing MZ B cell development and relatively strong 
BCR signaling follicular B cell development (Cariappa et al., 2001; Kraus et al., 2001; 
Samardzic et al., 2002). Receptors such as S1PR1 as well as integrins, including LFA1 and α4β1 
on MZ B cells, which bind to ICAM1 and VCAM1, respectively, expressed on MZ stromal cells, 
facilitate the migration and retention of MZ B cells and may also contribute to their maturation 










Chapter 2: Clearance of Chikungunya virus infection in lymphoid tissues is promoted by 
treatment with an agonistic anti-CD137 antibody 
 
ABSTRACT  
CD137, a member of the tumor necrosis factor receptor superfamily of cell surface 
proteins, acts as a costimulatory receptor on T cells, natural killer cells, B cell subsets, and some 
dendritic cells. Agonistic anti-CD137 monoclonal antibody (mAb) therapy has been combined 
with other chemotherapeutic agents in human cancer trials. Based on its ability to promote tumor 
clearance, we hypothesized that anti-CD137 mAb might activate immune responses and resolve 
chronic viral infections. We evaluated anti-CD137 mAb therapy in a mouse infection model of 
chikungunya virus (CHIKV), an alphavirus that causes chronic polyarthritis in humans, and is 
associated with reservoirs of CHIKV RNA that are not cleared efficiently by adaptive immune 
responses. Analysis of viral tropism revealed that CHIKV RNA preferentially was present in 
splenic B cells and follicular dendritic cells during the persistent phase of infection, and animals 
lacking B cells did not develop persistent CHIKV infection in lymphoid tissue. Anti-CD137 
mAb treatment resulted in a T cell-dependent clearance of CHIKV RNA in lymphoid tissue, 
although this effect was not observed in musculoskeletal tissue. The clearance of CHIKV RNA 
from lymphoid tissue by anti-CD137 mAb was associated with reductions in numbers of 
germinal center B cells and follicular dendritic cells. Similar results were observed with anti-
CD137 mAb treatment of mice infected with Mayaro virus (MAYV), a related arthritogenic 
alphavirus. Thus, anti-CD137 mAb treatment promotes resolution of chronic alphavirus infection 





Targeting of CD137 with agonistic monoclonal antibody (mAb) enhances spontaneous 
and Ab-dependent cell-mediated cytotoxicity by natural killer (NK) cells and proliferation and 
survival of CD8+ T cells. Anti-CD137 mAb also enhances antigen presentation by promoting 
costimulatory activity of dendritic cells (DCs) and by inhibiting the functions of regulatory T 
cells (Tregs) (Yonezawa et al., 2015). Based on preclinical studies demonstrating anti-CD137 
mAb as a promising cancer immunotherapy (Cuadros et al., 2005; Ito et al., 2004; Lee et al., 
2011; Lee et al., 2004; Wei et al., 2013), clinical trials in humans that combine anti-CD137 mAb 
with conventional chemotherapies have been initiated for the treatment of metastatic solid 
tumors, non-small cell lung cancer, melanoma, non-Hodgkin’s B cell lymphoma, colorectal 
cancer, and multiple myeloma (Yonezawa et al., 2015).  
Chikungunya virus (CHIKV) is a re-emerging alphavirus of the Togaviridae family and 
is transmitted by Aedes species mosquitoes. CHIKV was first isolated in Tanzania in 1952 and 
historically caused infections in Africa and Asia (Staples et al., 2009). In 2013, CHIKV spread 
into South and Central America, and an epidemic caused over 1.8 million infections including 
cases in the United States (Petersen and Powers, 2016). Infected individuals present with fever, 
rash, malaise, myalgia and polyarthritis (Simon et al., 2011). Although symptoms can resolve 
within a few weeks, 30 to 60% of individuals report persistent musculoskeletal pain months to 
years after initial diagnosis (Rodriguez-Morales et al., 2015; Rodriguez-Morales et al., 2016; 
Sissoko et al., 2009). Indeed, CHIKV RNA and protein have been detected in perivascular 
synovial macrophages at 18 months after infection (Hoarau et al., 2010). Persistent viral RNA in 
cells may act as a pathogen-associated molecular pattern (PAMP) and contribute to CHIKV-
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induced inflammation and arthritis (Magnusson et al., 2006; McCarthy and Morrison, 2017; Zare 
et al., 2004).  
In murine models of CHIKV, infectious virus is cleared from the blood and most tissues 
by 7 days post-infection (dpi). However, CHIKV RNA can be detected in musculoskeletal 
tissues, the spleen, and lymph nodes of immunocompetent mice for months (Hawman et al., 
2013). Although combinations of anti-CHIKV monoclonal antibody with CTLA4-Ig, an 
immunomodulatory drug, controlled CHIKV arthritis in mice (Miner et al., 2017), neither 
antiviral antibody alone nor in combination with CTLA4-Ig cleared CHIKV RNA from sites of 
persistence when administered after infection. Based on studies in cancer models, we 
hypothesized that an agonistic anti-CD137 mAb could activate immune responses that resolve 
chronic viral infections. Here, we evaluated the activity of anti-CD137 mAb in a model of 
CHIKV arthritis in immunocompetent C57BL/6 mice. Treatment with an agonistic anti-CD137 
mAb promoted clearance of persistent CHIKV RNA in the spleen and draining lymph node 
(DLN), and this effect required the presence of CD4+ and CD8+ T cells. However, clearance was 
not observed in musculoskeletal tissues. Viral RNA tropism studies revealed that B cells and 
follicular dendritic cells (FDCs) harbored much of the CHIKV RNA in lymphoid tissues. 
Unexpectedly, anti-CD137 mAb treatment resulted in reduced numbers of germinal center B 
cells and FDCs compared with isotype control mAb-treated animals. Thus, anti-CD137 mAb 
treatment cleared viral RNA in the spleen through either direct killing or indirect effects by T 
cells. As similar results were seen in mice with a second emerging alphavirus, Mayaro virus 
(MAYV), anti-CD137 mAb treatment resolves chronic alphavirus infection in lymphoid tissues 
by reducing the number of germinal center B cells and FDCs, which are the primary viral 
reservoirs in these tissues. 
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MATERIALS AND METHODS 
Viruses and cells. A recombinant CHIKV La Reunion OPY1 strain was provided by S. 
Higgs (Kansas State University) and generated from in vitro transcribed cDNA as described 
(Tsetsarkin et al., 2006). The resultant virus was propagated once in C6/36 Aedes albopictus 
cells and titrated using Vero cells as described (Pal et al., 2013). CHIKV SL15649 was generated 
in BHK21 cells from in vitro transcribed cDNA as described (Morrison et al., 2011). The MAYV 
BeH407 strain was provided by the World Reference Center for Arboviruses (S. Weaver, K. 
Plante, and R. Tesh) and propagated in Vero cells. 
Animal studies. All animal experiments were performed in accordance and with 
approval of Washington University and University of Colorado School of Medicine Institutional 
Animal Care and Use Committee guidelines. C57BL/6J (catalog# 000664), B6.129S2-
Ighmtm1Cgn/J (catalog# 002288; abbreviated mMT) and B6.129P2-Tcrbtm1Mom Tcrdtm1Mom/J 
(catalog# 002121; abbreviated TCRbd-/-) were purchased from Jackson Laboratories. CD137-/- 
mice (Kwon et al., 2002) were obtained as a gift from Michael Croft (La Jolla Institute for 
Immunology). MD4 mice (Mason et al., 1992) in a mMT B cell-deficient genetic background 
were generated at the University of Colorado by crossing the MD4 transgene (Jackson 
Laboratories; catalog# 002595) onto the mMT B cell-deficient background. At 4 weeks of age, 
male mice anesthesized with ketamine hydrochloride (80 mg/kg) and xylazine (15 mg/kg) were 
inoculated subcutaneously in the left rear footpad with 103 focus-forming units (FFU) of CHIKV 
or MAYV in 10 ml of PBS. Foot swelling was measured daily with digital calipers (54-100-004-
2, Fowler). At the termination of experiments, mice were euthanized and perfused via 
intracardiac injection with PBS. Tissues were harvested and stored at -80°C. 
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Quantitative reverse transcription PCR (qRT-PCR). Viral RNA was extracted from 
tissue homogenates using the RNeasy Mini Kit (74182, Qiagen). To extract viral RNA from 
paraformaldehyde (PFA) fixed cells, the RNeasy kit for purification of total RNA from formalin-
fixed, paraffin-embedded tissue sections (73504, Qiagen) was used according to the 
manufacturer’s protocol. qRT-PCR was performed using the TaqMan RNA-to-CT 1-Step Kit 
(Applied Biosystems) with a CHIKV E1- or MAYV E2-specific primer/probe set (Bellini et al., 
2012; Long et al., 2011). The extracted RNA was compared to a standard curve generated from 
RNA extracted from a CHIKV or MAYV stock to determine FFU equivalents. To quantify 
CHIKV genomic and subgenomic RNA levels in the spleen, random primed cDNA was used as 
a template for CHIKV sequence-specific forward (CHIKV2444, 5’- 
TTTGCGTGCCACTCTGG-3’) and CHIKV sequence-specific reverse (CHIKV2524, 5’- 
CGGGTCACCACAAAGTACAA-3’) primers and a CHIKV sequence-specific TaqMan probe 
(CHIKV2467, 5’FAM- ACTTGCTTTGATCGCCTTGGTGAGA-3’) to amplify a region of the 
nsP2 gene. The same random primed cDNA also was used as a template for CHIKV sequence-
specific forward (CHIKV10239, 5’-CGGCGTCTACCCATTTAT GT-3’) and CHIKV sequence-
specific reverse (CHIKV10363, 5’-CCCTG TATGCTGATGCAAATTC-3’) primers and a 
CHIKV sequence-specific TaqMan probe (CHIKV10290, 5’-FAM-
AAACACGCAGTTGAGCGAA GCAC-MGB-3’) that amplified a region in the E1 gene. A 
standard curve composed of 10-fold dilutions from 107 to 100 copies of CHIKV positive-strand 
genomic RNA, synthesized in vitro and spiked into RNA from BHK21 cells was used to 
determine the nsP1 and E1 gene copy number and confirm that the two assays amplified with 
similar efficiencies. To determine the relative abundance of the subgenomic RNA compared with 
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full-length genomic RNA, the data were expressed as a ratio of the E1 to nsP2 gene copy 
number.  
Antibodies and cell depletions. Anti-CD137 mAb (clone 2A, rat Ig2a mAb) has been 
described previously (Wilcox et al., 2002b). Antibody was purified from hybridoma supernatants 
by protein G affinity chromatography by a commercial vendor (BioXCell). Anti-CD4 (clone 
GK1.5), anti-CD8 (clone YTS169.4), anti-NK1.1 (clone PK136), anti-Ly6G (clone 1A8), anti-
CD40L (clone MR-1), rat IgG2b isotype control (clone LTF-2) for CD4+ and CD8+ T cell 
depletion, mouse IgG2a (clone C1.18.4) for NK and B cell depletion, rat IgG2a isotype control 
(clone 2A3) for neutrophil depletion and polyclonal Armenian hamster IgG for CD40L blockade 
were purchased from BioXCell. Anti-CD20 (clone 5D2) was obtained from Genentech. Mice 
were administered 400 mg of anti-CD137 or rat Ig2a isotype control mAb (clone 2A3, BioXCell) 
via intraperitoneal (i.p.) route at 2 dpi. For cell depletion studies, mice were administered 300 mg 
of anti-CD4 mAb, 500 mg of anti-CD8 mAb, or 200 mg of anti-NK1.1 mAb on 2 dpi and every 
4 days thereafter until 14 dpi or 500 mg of anti-Ly6G antibody on 2 dpi and every 2 days 
thereafter until 14 dpi. For B cell depletion, mice were administered 200 mg of anti-CD20 mAb 
on 2 dpi. For CD40L block, mice were administered 500 mg of anti-CD40L mAb on 2 dpi and 
every 3 days thereafter until 14 dpi. 
RNA in situ hybridization (ISH). Uninfected and infected mice were sacrificed and 
perfused extensively via intracardiac injection of PBS. The spleen was dissected and fixed in 1% 
PFA in PBS for 2 h at room temperature and transferred to 10% sucrose in PBS at 4°C. After 
incubation overnight, tissues were placed in 30% sucrose in PBS at 4°C overnight and frozen in 
Tissue Tek Compound (catalog # 4583, Sakura) at -80°C. Tissues were cut in 10 μm sections. 
Viral RNA ISH was performed using RNAscope 2.5 (Advanced Cell Diagnostics) according to 
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the manufacturer’s instructions. The probe targeting CHIKV RNA was designed and synthesized 
by Advanced Cell Diagnostics (catalog # 479501). All samples were visualized using a Nikon 
Eclipse microscope with a QICAM 12-bit camera (QImaging) and processed with QCapture 
software. 
Immune cell analysis. Ipsilateral feet from CHIKV-infected mice were skinned and 
incubated for 2 h at 37oC in 10 ml of digestion buffer (2.5 mg/ml collagenase (Sigma) and 10 
mg/mL DNase I (Sigma) in RPMI 1640 medium containing 10% fetal bovine serum (FBS)). The 
cell suspension was passed through a 70 mm cell strainer. After centrifugation, cells were 
washed with 1% FBS in Hank’s Balanced Salt Solution, followed by another round of 
centrifugation and washing. Cells were resuspended in washing buffer (5% FBS in PBS) at 5 x 
106 cells/ml and incubated with 2.5 mg of anti-mouse CD16/32 antibody (101302, Biolegend) 
per 106 cells for 20 min on ice. Cells then were stained with BV605-conjugated anti-CD45 
(103140, Biolegend), FITC-conjugated anti-CD3ε (11-0031-85, Invitrogen), PE-conjugated anti-
CD4 (553049, BD), PerCP-Cy5.5-conjugated anti-CD8α (100734, Biolegend), PE-Cy7-
conjugated anti-NK1.1 (108714, Biolegend), APC-Cy7-conjugated anti-CD19 (115530, 
Biolegend), Brilliant Violet 421-conjugated anti-Ly6C (562727, BD), Alexa 700-conjugated 
anti-Ly6G (127622, Biolegend) antibody. Subsequently, cells were fixed and permeabilized with 
eBioscience FoxP3/Transcription Factor Staining kit and incubated with Alexa 647-conjugated 
anti-FoxP3 (126408, Biolegend) antibody. 
Spleens from CHIKV-infected mice were minced and incubated for 30 min at 37oC in 2 
ml digestion buffer (1 mg/ml collagenase (Sigma) and 100 mg/mL DNase I (Sigma) in 
Dulbecco’s modified Eagle’s medium containing 2% FBS) in a 24-well plate. The cell 
suspension was passed through a 100 mm cell strainer. After rinsing with 10% FBS, 5 mM 
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EDTA in DMEM, erythrocytes were lysed with 1 ml of ACK Lysing Buffer (Gibco) for 2 min. 
Cells were washed with DMEM and centrifuged, followed by rinsing with washing buffer (2% 
FBS, 5mM EDTA in PBS). After centrifugation, cells were resuspended in washing buffer at 5 x 
108 cells/ml and incubated with 2.5 mg of anti-mouse CD16/32 antibody (101302, Biolegend) 
per 108 cells for 20 min on ice. Then, cells were stained with BV605-conjugated anti-CD45 
(103140, Biolegend), PE-Cy7-conjugated anti-CD3 (100320, Biolegend), APC-Cy7-conjugated 
anti-CD19 (115530, Biolegend), PerCP-Cy5.5-conjugated anti-CD11c (117328, Biolegend), 
FITC-conjugated anti-CD21/35 (553818, BD Biosciences), Brilliant Violet 421-conjugated anti-
CD54 (564704, BD), PE-conjugated anti-CD95 (554258, BD Biosciences) antibody and biotin-
conjugated PNA (B-1075, Vector). To confirm CD137 expression, cells were stained with 
biotin-conjugated anti-CD137 (106104, Biolegend). Cells then were washed and incubated with 
Alexa647-conjugated streptavidin (S32357, Invitrogen). Subsequently, cells were fixed with BD 
FACS Lysing Solution, processed on a LSR Fortessa X-20 (BD Biosciences) flow cytometer, 
and analyzed using BD FACSDiva and FlowJo software. For fluorescence-activated cell sorting, 
a BD FACS Aria II was used. 
Serum anti-CHIKV IgG ELISA assay. MaxiSorp 96-well flat-bottom ELISA plates 
(Thermo Fisher) were coated with 2 µg/ml of CHIKV E2 protein (a gift of Melissa Barrow 
(Washington University in St. Louis)) (Pal et al., 2013) overnight at 4°C. Plates were washed 
with ELISA wash buffer (PBS, 0.05% Tween 20) and blocked with blocking buffer (PBS, 5% 
FBS) for 4 h at 37°C. Sera from CHIKV-infected mice were added in 3-fold dilutions starting 
with a 1/100 dilution. After incubating for 1 h at room temperature, plates were washed with 
ELISA wash buffer. Plates were incubated with biotinylated anti-IgG (115-065-062, Jackson 
ImmunoResearch) for 1 h at room temperature. After washing, plates were incubated with 
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streptavidin-conjugated HRP (SA-5004, Vector Laboratories) for 30 min at room temperature. 
After washing sequentially with ELISA buffer and PBS, substrate solution (Thermo Fisher) was 
added. The reaction was quenched with 2N H2SO4. The plates were read using a Synergy H1 
Hybrid Reader (BioTek). Optical density (OD) value of naïve serum was subtracted from OD 
values of samples, and non-linear regression curves were calculated for each sample. 50% 
binding point was defined as the dilution to have a half-maximal optical density.  
Statistical analysis. All data were analyzed with GraphPad Prism software. For viral 
RNA analysis and immune cell analysis, data were analyzed by the Mann-Whitney test, Kruskal-
Wallis ANOVA with Dunn’s post-test, or two-way ANOVA with Sidak post-test. P values of 





Anti-CD137 mAb treatment reduces CHIKV RNA levels in lymphoid but not 
musculoskeletal tissues. We hypothesized that agonistic anti-CD137 mAb might stimulate the 
immune system to clear chronic viral infections, analogous to its ability to reduce tumor burden 
(Yonezawa et al., 2015). To test this idea, we used a murine model of CHIKV infection. Four 
week-old wild-type C57BL/6 male mice inoculated subcutaneously with CHIKV in the foot 
develop a biphasic pattern of joint swelling with persistent viral RNA present in the 
musculoskeletal tissues of the ipsilateral and contralateral feet, the spleen, and the DLN (Fig 2.1 
and (Hawman et al., 2013)); this viral RNA is maintained although infectious virus cannot be 
recovered after 7 dpi in immunocompetent mice (Poo et al., 2014b). CHIKV-infected mice 
treated therapeutically with agonistic anti-CD137 mAb at 2 dpi developed increased foot 
swelling from 7 to 10 dpi compared with isotype control mAb-treated animals (Fig 2.1A). 
Associated with this, at 7 dpi, we observed increased numbers of CD8+ T cells (3.3-fold, P < 
0.01) and Ly6G+ neutrophils (3.0-fold, P < 0.01) in the joints of anti-CD137 mAb-treated mice 
compared with isotype control mAb-treated animals (Fig 2.1B). 
Despite the changes in foot swelling induced by anti-CD137 mAb treatment, no 
differences in viral RNA levels were observed in the ipsilateral or contralateral feet at 7, 14 or 28 
dpi (Fig 2.1C-E). Similarly, the amount of CHIKV RNA in ipsilateral or contralateral feet did 
not change compared with isotype control mAb-treated animals at 14 dpi when mice were treated 
with anti-CD137 mAb at day 0, the same time as virus inoculation (Fig 2.1H-J). 
           Although anti-CD137 mAb treatment at 0 or 2 dpi failed to clear CHIKV RNA in 
musculoskeletal tissues, we observed reduced viral RNA levels in the spleen at 7 dpi compared 
with isotype control mAb (Fig 2.1F). At 14 and 28 dpi, anti-CD137 mAb-treated mice showed 
greater reductions in CHIKV RNA in the spleen (~130 to 220-fold, P < 0.0001) compared with 
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isotype control mAb treated animals. In most (7 of 10) animals treated with a single dose of anti-
CD137 at 2 dpi, viral RNA was not detected in the spleen at 28 dpi (Fig 2.1F). Reduced levels 
(110-fold, P < 0.0001) of CHIKV RNA also were observed at 14 dpi in the DLN after anti-
CD137 mAb treatment (Fig 2.1G). However, at 28 dpi, CHIKV RNA in the DLN was absent in 
most anti-CD137 and isotype control mAb-treated animals (Fig 2.1G). When mice were treated 
with anti-CD137 mAb at 0 dpi, the amount of CHIKV RNA in the spleen and DLN at 14 dpi also 
was substantially reduced (140 to 7,000-fold, P < 0.05) compared with isotype control mAb-
treated animals (Fig 2.1K-L). We confirmed the specificity of the effect; treatment of CHIKV-
infected CD137-/- mice with agonistic anti-CD137 mAb at 2 dpi did not reduce viral RNA levels 
in the spleen (Fig 2.1M).  
Effect of anti-CD137 mAb on CHIKV tropism in the spleen. To begin to elucidate 
how anti-CD137 mAb treatment promoted clearance of CHIKV RNA in the spleen, we explored 
the cellular tropism of the virus in this tissue, which has remained undefined. Initially, we 
performed viral RNA in situ hybridization (ISH) on spleens from CHIKV-infected mice treated 
with anti-CD137 or isotype control mAb. At 7 dpi, much of the viral RNA was present in the 
center of lymphoid follicles of anti-CD137 or isotype control mAb-treated animals (Fig 2.2A-B). 
To define the cell types harboring CHIKV RNA, we sorted splenocyte subsets at 7 and 14 dpi by 
flow cytometry and performed qRT-PCR; cells were fixed with paraformaldehyde prior to 
sorting because of containment issues, as infectious CHIKV is a biosafety level 3 agent. At 7 and 
14 dpi, follicular dendritic cells (FDCs) and germinal center B cells contained the highest 
relative levels of CHIKV RNA on a per cell basis in the spleens of isotype control mAb-treated 
animals (Fig 2.2C). When anti-CD137 mAb treatment was administered at 2 dpi, CHIKV RNA 
preferentially was cleared from FDCs at 7 dpi and not appreciably detected in any splenocyte 
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subsets at 14 dpi. During productive CHIKV infection, the subgenomic mRNA segment 
encoding the structural proteins (C-E3-E2-6K-E1) is preferentially transcribed compared to the 
genomic RNA (Carrasco et al., 2018). This results in more copies of structural proteins, such as 
E1, than the non-structural proteins. As a surrogate assay for detecting infectious virus in the 
spleen, we measured the ratio of subgenomic (E1 RNA) to genomic (nsP2 RNA) RNA by qRT-
PCR. At least up through 14 dpi, the ratio of E1 RNA compared to nsP2 RNA was greater than 1 
(Fig 2.2D-F), suggesting active infection. 
In addition to altering CHIKV persistence in the spleen, we speculated that anti-CD137 
mAb treatment might impact specific immune cell populations after infection. Anti-CD137 mAb 
treatment did not diminish the total number of leukocytes in the spleen (Fig 2.3A), and we even 
observed a small increase (1.6-fold increase, P < 0.01) in the number CD3+ T cells at 14 dpi. 
(Fig 2.3B). However, we did observe a small decrease (1.4-fold decrease, P < 0.01) in the 
number of CD19+ B cells (Fig 2.3C) and markedly reduced (up to ~40-fold, P < 0.01) numbers 
of PNA+CD95+ or GL7+CD95+ germinal center B cells and CD45-CD54+CD21/35+ FDCs at 7 
and 14 dpi (Fig 2.3D-G). To test whether inhibition of germinal center development affected 
antiviral antibody responses, we measured anti-CHIKV IgG levels in the serum of infected mice 
at 30 dpi. Consistent with the reduced numbers of germinal center B cells, we observed lower 
(32-fold, P < 0.001) levels of anti-CHIKV IgG in anti-CD137 mAb-treated than isotype control 
mAb-treated animals (Fig 2.3H). 
B cells are required for persistence of CHIKV RNA in the spleen. Since splenic 
germinal center B cells and FDCs showed the highest quantities of viral RNA on a per cell basis 
after CHIKV infection, we further evaluated the contribution of these cells to persistence of 
CHIKV RNA in the spleen. Initially, at 2 dpi we treated isotype control mAb-treated mice with 
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an anti-CD40L-blocking mAb, which inhibits engagement of CD40L on B cells with its receptor 
CD40 on T helper cells and results in impaired germinal center formation (Baumjohann et al., 
2013). As expected, administration of CD40L-blocking mAb reduced the number of germinal 
center B cells and FDCs at 14 dpi by 108- and 7-fold, respectively (Fig 2.4A-D). This depletion 
was associated with an approximately 5-fold reduction in CHIKV RNA in the spleen, although 
the difference did not attain statistical significance (Fig 2.4E, comparison of black circles). In 
comparison, treatment with anti-CD137 mAb in combination with CD40L-blocking mAb or the 
block isotype control mAb reduced viral RNA levels in the spleen compared with treatment with 
isotype control mAb in combination with CD40L-blocking mAb (123-fold, P < 0.05) or block 
isotype control mAb (660-fold, P < 0.001), respectively (Fig 2.4E, comparison of black and red 
circles on the left-side or right-side, respectively). Collectively, these experiments show that 
although germinal center B cells and FDCs contain high levels of CHIKV RNA in the spleens of 
isotype control mAb-treated mice, other cell populations contribute to the persistence of CHIKV 
RNA. 
Based on these data, we speculated that non-germinal center B cells also harbored 
CHIKV RNA in the spleen. Indeed, when we depleted all CD20+ B cells using an anti-CD20 
mAb at 2 dpi we observed a 75-fold reduction (P < 0.001) in CHIKV RNA in the spleen at 14 
dpi (Fig 2.4F-G; comparison of black circles). To corroborate these data, mMT (B cell-deficient) 
mice were inoculated with CHIKV and treated with anti-CD137 mAb at 2 dpi. Viral RNA levels 
at 7 dpi in the spleens of mMT mice were lower than WT mice with anti-CD137 mAb treatment 
(87-fold, P < 0.001) or without it (299-fold, P < 0.001), respectively (Fig 2.1D and Fig 2.4H). 
However, the levels of viral RNA in the spleens of anti-CD137 mAb-treated and isotype control 
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mAb-treated mMT mice at 7 dpi were similar. At 14 dpi, almost no CHIKV RNA was detected 
in the spleen of these mice with or without anti-CD137 mAb treatment (Fig 2.4H).  
 Antigen in the form of immune complexes can be captured by cells expressing Fc-g or 
complement receptors, or antigen can be directly captured by B cell receptors. We next tested 
whether CHIKV-specific antibody was required for the persistence of viral RNA in the spleen. 
To assess this, we used transgenic MD4 mice in a mMT background; these mice have B cell 
receptors specific only for hen egg lysozyme (HEL) (Fig 2.4I) (Mason et al., 1992). At 14 dpi, 
viral RNA was detected in the spleens of MD4 mice, albeit at substantially lower levels than WT 
mice, whereas almost no viral RNA was measured from the spleens of mMT mice (Fig 2.4J). 
Thus, the antigen-specificity of B cells contributes to persistence of CHIKV RNA in the mouse 
spleen. 
T cells are required for anti-CD137-mediated clearance of CHIKV in the spleen. We 
hypothesized that agonistic anti-CD137 mAb cleared CHIKV RNA in lymphoid tissues by 
activating CD137+ immune cells with effector activity (Yonezawa et al., 2015). We detected 
CD137 expression by flow cytometry on splenic CD4+ and CD8+ T cells, NK cells and NKT 
cells in CHIKV-infected mice at 2 dpi (Fig 2.5). To define the cells responsible for anti-CD137 
mAb-mediated clearance of CHIKV RNA, we performed anti-CD137 mAb treatment 
experiments in mice depleted of NK cells, CD8+ T cells, CD4+ T cells, or neutrophils. 
Administration of anti-CD137 mAb in NK cell, CD8+ T cell, or CD4+ T cell depleted mice 
resulted in diminished CHIKV RNA levels in the spleen at 14 dpi, although the reduction was 
only 2 to 5-fold less than with control non-depleting mAbs (Fig 2.6A-F). Ab-mediated depletion 
of both CD4+ and CD8+ T cells resulted in 9-fold less of a clearance effect by anti-CD137 mAb 
(Fig 2.6G-H). Similarly, Ab-mediated triple depletion of CD4+ and CD8+ T cells as well as NK 
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cells resulted in 21-fold less clearance by anti-CD137 mAb (Fig 2.6I-J). In comparison, 
depletion of neutrophils did not affect anti-CD137 mAb-mediated clearance of CHIKV RNA in 
the spleen at 14 dpi (Fig 2.6K-L). Consistent with a dominant role for CD3+ cells in mediating 
clearance of CHIKV RNA in the spleen, the effect of anti-CD137 mAb was abolished 
completely in TCRβδ-/- mice, which lack all T cell and NKT cell subsets (Fig 2.6M). 
 Anti-CD137 mAb treatment reduces Mayaro virus RNA levels. We assessed the 
effect anti-CD137 mAb on a second alphavirus, MAYV, to determine whether the clearance 
phenotype was specific to CHIKV. In contrast to that observed with CHIKV-infected mice, 
treatment with anti-CD137 mAb reduced (8-fold, P < 0.0001) viral RNA level in the ipsilateral 
foot of MAYV-infected mice at 14 dpi (Fig 2.7A), although viral RNA levels in the contralateral 
foot of anti-CD137 and isotype control mAb-treated mice were similar (Fig 2.7B). Similar to 
CHIKV-infected mice, anti-CD137 mAb treatment resulted in markedly reduced MAYV RNA 
levels in the spleen (241-fold, P < 0.0001) and DLN (5,962-fold, P < 0.001) at 14 dpi (Fig 2.7C-
D). Thus, anti-CD137 mAb-mediated clearance of viral RNA in lymphoid tissues occurred in the 
context of multiple alphavirus infections in mice, whereas reduction of viral RNA in 






 In this study, we observed that agonistic anti-CD137 mAb administered at 2 dpi cleared 
CHIKV RNA in the spleen and DLN by 28 dpi although viral RNA in musculoskeletal tissues of 
the foot persisted. In a parallel model of infection with MAYV, a second arthritogenic 
alphavirus, anti-CD137 mAb treatment also reduced MAYV RNA levels in the spleen and DLN 
by 14 dpi. However, in the MAYV model, a partial clearance effect was observed in the 
ipsilateral but not contralateral foot. Based on our cell sorting and tropism data, in the spleen, 
germinal center B cells and FDCs were associated with the highest levels of viral RNA on a per 
cell basis at 7 and 14 dpi. Flow cytometric analysis revealed that anti-CD137 mAb treatment 
reduced the number of germinal center B cells and FDCs, and this was associated with 
diminished anti-CHIKV IgG responses. Inhibition of germinal center formation by anti-CD137 
mAb has been reported in mice immunized with sheep red blood cells or keyhole limpet 
hemocyanin (Sun et al., 2005). When B cells were depleted using anti-CD20 mAb, CHIKV RNA 
in the spleen also was reduced at 14 dpi. Together, these data suggest a key role for B cells in 
maintaining persistent CHIKV RNA in the spleen. Consistent with these results mMT mice 
lacking B cells had almost no detectable viral RNA in the spleen at 14 dpi, and MD4 transgenic 
mice, which have B cells specific for HEL, also had less CHIKV RNA in the spleen at 14 dpi. 
These data suggest that antigen-specific B cells are responsible for the persistence of CHIKV 
RNA in mouse spleen. Anti-CD137 mAb-mediated clearance of CHIKV RNA in the spleen was 
diminished in anti-NK 1.1, anti-CD4, and anti-CD8 treated mice and abrogated in TCRβδ-/- mice, 
which lack CD4+ and CD8+ T cells, NKT cells, and gd T cells in the spleen. Thus, anti-CD137 
mAb-mediated clearance of CHIKV in lymphoid tissues is dependent primarily on T cells. 
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The basis of CHIKV RNA persistence in musculoskeletal tissues of infected animals 
remains a long-standing question in the field. Although anti-CD137 mAb treatment had marked 
effects in lymphoid tissues, it did not significantly alter CHIKV RNA levels in the ipsilateral or 
the contralateral feet at 7, 14, or 28 dpi. The lack of CHIKV RNA clearance in the 
musculoskeletal tissues after anti-CD137 mAb treatment may be due to the distinct viral tropism 
in these tissues. During the acute phase of infection, CHIKV is readily detected in skeletal 
muscle cells, synovial fibroblasts, and other non-hematopoietic cells in mice (Nair et al., 2017; 
Young et al., 2019). During the chronic phase, the reservoir of CHIKV in muscle and joint 
tissues is less clear, although experiments with a Cre-recombinase CHIKV strain and reporter 
mice showed fibroblasts and skeletal muscle cells harbor persistent viral RNA (Young et al., 
2019). In contrast to our observations in the CHIKV model, agonistic anti-CD137 mAb 
treatment reduced viral RNA levels in the ipsilateral foot in the MAYV model. Although further 
study is warranted, the cellular tropism of MAYV may differ with respect to CHIKV, as has 
been reported for other arthritogenic alphaviruses, such that additional infected cell types can be 
cleared by anti-CD137 activated T cells (Suhrbier and La Linn, 2004). 
Our experiments showed that in the spleen, germinal center B cells and FDCs are 
associated with high levels of CHIKV RNA at 7 and 14 dpi. Although viral RNA was readily 
detected, we did not recover infectious CHIKV from lymphoid tissues at these time points, as 
judged by plaque or focusing forming assays. Notwithstanding these data, we did observe higher 
E1:nsP2 RNA ratios consistent with productive CHIKV infection. Additionally, B cells may 
capture CHIKV immune complexes via surface complement and Fc-g receptors and transport it 
to FDCs in the B cell follicles (Cinamon et al., 2008; Heinen et al., 1986). Marginal zone B cells 
continuously shuttle between marginal zone and follicular areas, which can facilitate antigen 
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transport (Cinamon et al., 2008). Alternatively, immune complexes taken up by subcapsular 
sinus or marginal zone macrophages can be transferred to complement receptor 2 (CR2)-
expressing B cells, which then transport the immune complexes to CR2-expressing FDCs 
(Batista and Harwood, 2009). 
FDCs are believed to retain opsonized antigen for extended periods time periods and 
present it to cognate B cells to form germinal centers (Hanna and Szakal, 1968). As an example, 
human FDCs isolated from patients retain HIV for prolonged periods of time within non-
degradative cycling compartments (Heesters et al., 2015). Clearance of CHIKV RNA in the 
spleen after anti-CD137 mAb treatment correlated with reductions in the number of germinal 
center B cells and FDCs. Moreover, the level of viral RNA in the spleen was reduced in mMT or 
MD4 transgenic mice lacking CHIKV-specific B cells and Abs. Based on our tropism analysis, 
blocking studies with anti-CD40L mAb, depletion studies with anti-CD20 mAb and infection 
experiments in mMT B cell-deficient mice, it appears that multiple subtypes of B cells and FDCs 
retain much of the CHIKV RNA in lymphoid tissues during the subacute and chronic phases of 
infection. 
Anti-tumor mechanisms of anti-CD137 mAb activity are thought to depend on direct 
killing by CD8+ T cells and NK cells, enhanced proliferation and cytokine secretion by tumor-
specific T cells, and Ab-dependent cell-mediated cytotoxicity by NK cells at tumor sites 
(Yonezawa et al., 2015). In a mouse B cell lymphoma model, depletion of CD8+ T cells or NK 
cells abrogated the anti-tumor effect of anti-CD137 mAb (Houot et al., 2009). Although the anti-
tumor effect of anti-CD137 mAb is mediated through engagement of CD8+ T cells in most 
preclinical tumor models, the role of CD4+ T cells is less clear. Depletion of CD4+ T cells 
improved the therapeutic efficacy of anti-CD137 mAb in a mouse B cell lymphoma model 
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(Houot et al., 2009), whereas CD4+ T cells were required for anti-CD137 mAb-induced anti-
tumor immunity in a mouse mastocytoma model (Melero et al., 1997). Based on our cell 
depletion experiments, anti-CD137 mAb-mediated clearance of persistent CHIKV RNA was 
dependent only partially on NK cells, CD4+ and CD8+ T cells. However, anti-CD137 mAb-
mediated clearance of CHIKV RNA was abrogated in TCRβδ-/- mice. Immune cell subsets other 
than conventional CD4+ or CD8+ T cells such as NKT cells that are absent in these mice could 
contribute to anti-CD137 mAb-mediated clearance of CHIKV RNA in the spleen. Because B 
cells are a major reservoir of persistent CHIKV RNA in the spleen, we hypothesize that anti-
CD137 mAb clears persistent CHIKV RNA in the spleen and DLN by targeting B cells. Further 
study is necessary to define how activation by anti-CD137 mAb induces T cells and possibly 
NKT cells to lyse and/or prevent expansion of B cells, and whether any of this process is 
antigen-specific. 
Our study helps to elucidate the basis for retention of CHIKV RNA in secondary 
lymphoid tissues. The clearance of CHIKV RNA coincided with a reduction in B cells and FDCs 
that was mediated by anti-CD137 mAb treatment and T cells. These effects on germinal center 
formation may be relevant for infections and vaccinations that occur in patients treated with 
agonistic anti-CD137 mAb therapies for cancers. Although further study is warranted, treatment 
with anti-CD137 mAbs might blunt humoral response to newly-administered vaccines or 








Figure 2.1. Anti-CD137 mAb treatment increases footpad swelling but reduces viral RNA 
level in the spleen and DLN. Four-week-old WT C57BL/6 male mice were inoculated with 103 
FFU of CHIKV-LR at day 0. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb 
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was administered via an i.p. route. (A) Foot swelling was measured with digital calipers (15-18 
mice per group). Each symbol represents a mean value of each group, and bars indicate standard 
deviation (two-way ANOVA with Sidak post-test; **, P < 0.01; ****, P < 0.0001). (B) 
Ipsilateral feet were harvested at 7 dpi and processed for flow cytometry to quantify immune cell 
infiltrates. (C) Experimental scheme for panels D-G. Ipsilateral (D) and contralateral (E) feet, 
spleen (F), and DLN (G) were harvested at 7, 14, and 28 dpi. Viral RNA was measured from 
tissue homogenates by qRT-PCR. (H) Experimental scheme of panels I-L. At the same time as 
virus inoculation, 400 mg of agonistic anti-CD137 mAb or isotype control was administered i.p. 
Ipsilateral (I) and contralateral (J) foot, spleen (K) and DLN (L) were harvested at 14 dpi, and 
viral RNA was measured from tissue homogenates by qRT-PCR. (M) Four-week-old CD137-/- 
C57BL/6 mice were inoculated with 103 FFU of CHIKV-LR at day 0. At 2 dpi, 400 mg of 
agonistic anti-CD137 or isotype control mAb was administered via an i.p. route. Spleens were 
harvested on 14 dpi. Viral RNA was measured from tissue homogenates by qRT-PCR. Each 
symbol represents an individual mouse, and bars indicate median values. Data in panels B, D-G, 
and I-M are pooled from 2 or 3 experiments (Mann-Whitney test: *, P < 0.05; **, P < 0.01; 






Figure 2.2. Germinal center B cells and FDCs harbor CHIKV viral RNA. Four-week-old 
WT C57BL/6 male mice were inoculated with 103 FFU of CHIKV-LR. At 2 dpi, 400 mg of 
agonistic anti-CD137 or isotype control mAb was administered via an i.p. route. (A) Spleens 
were harvested at 7 dpi, and viral RNA (brown) was visualized by ISH. Tissue sections were 
counterstained with Gill’s haematoxylin. Scale bar (50 mm). (B) Inset of panel A (black boxes) 
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visualized with higher magnification. Scale bar (10 mm). Yellow arrows indicate CHIKV RNA. 
(C) Spleens were harvested at 7 dpi (left panel) and 14 dpi (right panel), and bulk cells were 
fixed with paraformaldehyde and sorted using flow cytometry. Viral RNA in each sorted cell 
subset was measured by qRT-PCR and normalized to 18S. (D-F) Four-week-old WT C57BL/6 
male mice were inoculated with 103 PFU of CHIKV SL15649. Spleens were harvested at 3, 7, 
and 14 dpi, and CHIKV E1 (D) and nsP2 (E) RNA was measured from tissue homogenates by 
qRT-PCR. (F) The ratio of E1 RNA to nsP2 RNA was calculated. Data in this Figure are pooled 
from 2 experiments. Each symbol represents one mouse, and bars indicate median values (Mann-






Figure 2.3. Anti-CD137 mAb treatment reduces the number of germinal center B cells and 
FDCs. Four-week-old WT C57BL/6 male mice were inoculated with 103 FFU of CHIKV-LR. At 
2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb was administered via an i.p. route. 
The number of total CD45+ leukocytes (A), CD3+ T cells (B), CD19+ B cells (C), PNA+CD95+ 
or GL7+CD95+ germinal center B cells (D-E) and CD45-CD54+CD21/35+ FDCs (F-G) in the 
spleen at 14 dpi was analyzed by flow cytometry. Representative flow cytometry dot plots of (D) 
germinal center B cells and (F) FDCs are shown. (H) Serum was harvested at 30 dpi, and anti-
CHIKV IgG titer was measured by ELISA. Each symbol represents an individual mouse, and 
bars indicate median values. Data in this Figure were pooled from 2 to 3 experiments (Mann-






Figure 2.4. B cells are required for persistence of CHIKV RNA in the spleen. (A-G) Four-
week-old WT C57BL/6 male mice were inoculated with 103 FFU of CHIKV-LR. At 2 dpi, 400 
mg of agonistic anti-CD137 or isotype control mAb in combination with CD40L-blocking or 
isotype (block) control mAb (A-E) or anti-CD20 depleting or depletion isotype control mAb (F-
G) was administered via an i.p. route. Spleens were harvested at 14 dpi, and the number of 
PNA+CD95+ germinal center B cells (A-B) and CD45-CD54+CD21/35+ FDCs (C-D) was 
determined after flow cytometry. Representative flow cytometry dot plots of germinal center B 
cells (A), FDCs (C) and CD19+ B cells (F) are shown. (E and G) Viral RNA was measured from 
tissue homogenates by qRT-PCR. (H-J) 4-week-old mMT mice (H) or MD4 transgenic mice in 
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a mMT background (I-J) were inoculated with 103 FFU of CHIKV-LR. (H) At 2 dpi, 400 mg of 
agonistic anti-CD137 or isotype control mAb was administered. Spleens were harvested at 7 or 
14 dpi, and viral RNA was measured. Each symbol (H and J) represents an individual mouse, 
and bars indicate median values (Kruskal-Wallis ANOVA with Dunn’s post-test: *, P < 0.05; **, 
P < 0.01; ***, P < 0.001; ****, P < 0.0001; n.s., not significant). (I) At 14 dpi, the spleen was 
removed and processed for flow cytometry. Splenocytes were gated on B220+CD19+ for B cells. 
Representative flow plots from each genotype are shown. WT B cells are IgMb+, and HEL-
specific (MD4) B cells are IgMa+. MD4 B cells were also confirmed by staining with HEL (data 








Figure 2.5. CD137 is expressed on splenic CD4+ and CD8+ T cells, NK cells, and NKT cells 
in CHIKV-infected mice at 2 dpi. Four-week-old WT C57BL/6 mice were inoculated with 103 
FFU of CHIKV-LR strain at day 0. At 2 dpi, spleens were harvested and processed for flow 
cytometry. Flow cytometry dot plots showing CD137 expression levels on CD4+ and CD8+ T 
cells, CD3-NK1.1+ NK cells, CD19+ B cells, MHC-II+CD11c+ DCs and CD3+NK1.1+ NKT cells. 





Figure 2.6. Anti-CD137 mAb-mediated clearance of CHIKV RNA in the spleen is abolished 
in mice lacking T cells. Four-week-old WT (A-L) or TCRbd-/- C57BL/6 (M) mice were 
inoculated with 103 FFU of CHIKV-LR. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype 
control mAb in combination with anti-NK1.1 depleting or depletion isotype control mAb (A-B), 
anti-CD8α depleting or depletion isotype control mAb (C-D), anti-CD4 depleting or depletion 
isotype control mAb (E-F), anti-CD8α and anti-CD4 depleting or depletion isotype control 
mAbs (G-H), anti-CD8α, anti-CD4 and anti-NK1.1 depleting or depletion isotype control mAb 
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(I-J) or anti-Ly6G depleting or depletion isotype control mAb (K-L) was administered via an i.p. 
route. All depleting and depletion isotype control mAbs were administered every 4 days, except 
for anti-Ly6G and isotype control mAbs, which were administered every 2 days. Spleens were 
harvested at 14 dpi, and viral RNA was measured from tissue homogenate by qRT-PCR. Data 
are pooled from 2 or 3 experiments. Each symbol represents an individual mouse, and bars 
indicate median values (Mann-Whitney test: ***, P < 0.001; ****, P < 0.0001). Representative 






Figure 2.7. Anti-CD137 mAb treatment reduces levels of MAYV RNA in the spleen, DLN 
and ipsilateral foot. Four-week-old WT C57BL/6 male mice were inoculated with 103 FFU of 
MAYV-BeH407. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb was 
administered via an i.p. route. Ipsilateral (A) and contralateral (B) feet, spleen (C), and DLN (D) 
were harvested at 14 dpi. Viral RNA was measured from tissue homogenates by qRT-PCR. Each 
symbol represents an individual mouse, and bars indicates median values. Data are pooled from 




Chapter 3: An agonistic anti-CD137 antibody disrupts lymphoid follicle structure and T 
cell-dependent antibody responses  
ABSTRACT 
CD137 is a costimulatory receptor expressed on natural killer cells, T cells, and subsets 
of dendritic cells. An agonistic monoclonal antibody (mAb) against CD137 has been used to 
reduce tumor burden or reverse autoimmunity in animal models and clinical trials. Here, we 
show that mice treated with an agonistic anti-CD137 mAb have reduced numbers of germinal 
center B (GC B) cells and follicular dendritic cells (FDCs) in lymphoid tissues. As a result, 
agonistic anti-CD137 mAb treatment impairs antibody responses to multiple T cell-dependent 
antigens including infectious virus, recombinant viral proteins, and conjugated haptens but not to 
a T cell-independent antigen or at homeostasis. These effects were not due to enhanced apoptosis 
or impaired proliferation of B cells but instead correlated with changes in lymphoid follicle 
structure and GC B cell dispersal, and were mediated by CD137 signaling in CD4+ and CD8+ T 
cells. Our experiments in mice suggest that agonistic anti-CD137 mAbs used in cancer and 







Agonistic monoclonal antibodies (mAbs) targeting the costimulatory receptor CD137 
enhance antibody-dependent cell-mediated cytotoxicity by NK cells and proliferation, functional 
activity, and survival of T cells (Yonezawa et al., 2015). Because of these functions, anti-CD137 
mAbs have been combined with chemotherapeutic and immunotherapeutic agents in human 
cancer clinical trials (Yonezawa et al., 2015). Anti-CD137 mAbs also have been evaluated in 
autoimmune disease animal models based on their ability to induce tolerogenic DCs and 
regulatory T cells (Lee et al., 2012; Seo et al., 2004).  
Germinal centers (GCs) in lymphoid tissues are complex anatomical sites where somatic 
hypermutation and antibody isotype switching occurs. GC B cells proliferate extensively and 
traffic through the light and dark zones as part of an antigen-driven affinity-based clonal 
selection process (reviewed in (Mesin et al., 2016)). In the light zone, GC B cells recognize 
cognate antigens and undergo selection with the cytokine-directed input of follicular helper T 
cells (Tfh), which themselves are modulated by follicular regulatory T cells (Tfr) (Linterman et 
al., 2011). GC B cells without strong affinity for antigens or without T cell help undergo 
apoptosis. The GC reaction culminates in the generation of the two arms of humoral immune 
memory, high-affinity memory B cells (MBCs) and terminally differentiated long-lived plasma 
cells (LLPCs), the latter of which are professional antibody-secreting cells. Apart from follicular 
B cells, lymphoid tissues also contain marginal zone (MZ) B cells, which express polyreactive B 
cell receptors (BCR), produce natural IgM and IgG antibodies, and protect against blood-borne 
bacterial infection in a T cell-independent manner (Cerutti et al., 2013; Tanigaki et al., 2002). 
While evaluating anti-CD137 mAb as a possible therapy for chronic alphavirus infection 
in mice, we unexpectedly observed reduced numbers of GC B cells (Hong et al., 2019). Here, we 
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evaluated the mechanistic basis and consequences of agonistic anti-CD137 mAb treatment on 
antibody and B cell responses in the context of immunization or virus infection in mice. During 
infection with chikungunya virus (CHIKV), an emerging arthritogenic alphavirus, anti-CD137 
mAb treatment resulted in reduced numbers of GC B cells, MBCs, and LLPCs. Administration 
of anti-CD137 mAb also dampened the serum antibody response in mice immunized with other 
T cell-dependent antigens (influenza virus hemagglutinin (HA) and 4-hydroxy-3-
nitrophenylacetyl hapten (NP)-conjugated keyhole limpet hemocyanin (KLH)), but not with a T 
cell-independent antigen (NP-Ficoll) or at homeostasis. The reduction of GC B cell numbers 
caused by anti-CD137 mAb was associated with altered GC architecture, attrition of stromal 
cells critical for GC formation and maintenance, and dispersal of GC B cells. Inhibition of GC 
formation by anti-CD137 required cell-intrinsic signaling of T cells. Thus, in mice, anti-CD137 
mAb-treatment results in activation of T cells that impairs GC development and induction of 






Anti-CD137 mAb treatment diminishes germinal centers, and antigen-specific 
memory B and long-lived plasma cells. Because we previously observed diminished GC 
numbers in CHIKV-infected mice treated with anti-CD137 mAb (Hong et al., 2019), we 
evaluated the effect on long-term memory B cell responses. Four-week-old C57BL/6 male mice 
were inoculated subcutaneously (s.c.) in the foot with CHIKV (day 0) and then injected via an 
intraperitoneal (i.p.) route with anti-CD137 mAb at 2 days post-infection (dpi) (Fig 3.1A). At 14 
dpi, mice treated with anti-CD137 mAb had slightly reduced numbers of CD19+ B cells in the 
spleen compared to isotype control mAb-treated animals (1.4-fold, P < 0.01; Fig 3.1B). 
However, the number of GC B cells (as determined by either peanut agglutinin lectin 
(PNA)+CD95+ or GL7+CD95+ staining) in the spleen at 14 dpi was reduced to a greater extent 
(33.3 to 43.3-fold, P ≤ 0.0001; Fig 3.1C-D). To assess the long-term consequence on the 
antibody response, serum was obtained at 7, 14, 30, 50, 65 and 90 dpi, and the spleen and bone 
marrow were harvested at 90 dpi to profile antigen-specific MBCs and LLPCs (Fig 3.1A). Anti-
CD137 mAb-treated mice had lower numbers of CHIKV-specific MBCs in the spleen (20.6-fold, 
P < 0.001) and LLPCs in the bone marrow (43.5-fold, P < 0.001) than isotype control mAb-
treated animals (Fig 3.1E-F). Serum anti-CHIKV IgG levels also were reduced in anti-CD137 
mAb-treated mice compared to isotype control mAb-treated animals beginning at 14 dpi (4.9 to 
33.1-fold, P ≤ 0.0001; Fig 3.1G). 
To test the effect of anti-CD137 mAb on a later stage of the GC reaction, we treated 
CHIKV-infected mice with anti-CD137 mAb at 14 dpi and analyzed cell numbers at 28 dpi (Fig 
3.1H). Although the number of total CD19+ B cells did not change (Fig 3.1I), the number of 
PNA+CD95+ GC B cells in anti-CD137 mAb-treated mice was decreased (142-fold, P ≤ 0.0001) 
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compared to isotype control mAb-treated animals (Fig 3.1J). We then evaluated the effect of 
anti-CD137 mAb on an established memory B cell response. CHIKV-infected mice were treated 
with anti-CD137 mAb at 56 dpi, a time when the GC reaction should be fully established 
(Bachmann et al., 1996; Mesin et al., 2016), and spleen and bone marrow were harvested at 90 
dpi for analysis (Fig 3.1K). Anti-CD137 mAb-treated mice showed similar number of CHIKV-
specific MBCs and only slightly reduced numbers (2-fold, P < 0.01) of CHIKV-specific LLPCs 
compared to isotype control mAb-treated animals (Fig 3.1L-M). Correspondingly, serum anti-
CHIKV IgG levels at 90 dpi were similar between mice treated at 56 dpi with anti-CD137 or 
isotype control mAb (Fig 3.1N). These data suggest that anti-CD137 mAb treatment inhibits the 
development of MBCs and LLPCs but has minimal effect on the maintenance of established 
memory B cell compartments. However, in naïve pathogen-free mice, anti-CD137 mAb 
treatment did not substantially alter the relatively low number of GC B cells seen at homeostasis 
(Fig 3.1O). 
Anti-CD137 mAb treatment reduces T cell-dependent but not -independent 
antibody responses. We evaluated the effect of anti-CD137 mAb treatment after immunization 
with model T cell-dependent (NP-KLH, TD) and T cell-independent (NP-Ficoll, TI) antigens 
(Mond et al., 1995). Four-week-old C57BL/6 male mice were immunized via i.p. route with NP-
KLH or NP-Ficoll and then treated with anti-CD137 mAb two days later. Sera were obtained at 
multiple time points post-immunization, and at the last time point bone marrow was harvested to 
profile LLPCs (Fig 3.2A and F). Spleens from a separate cohort of mice were harvested at 30 
days post-immunization to quantify MBCs. Anti-CD137 mAb treatment reduced the number of 
GC B cells (18-fold, P < 0.01) and antigen-specific LLPCs (12-fold, P < 0.0001) at 14 and 130 
days post-immunization, respectively, in mice administered NP-KLH (Fig 3.2B-C). The number 
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of NP-specific IgG+ MBCs also was reduced (7-fold, P < 0.001) at 30 days post-immunization 
(Fig 3.2D). Correspondingly, serum anti-NP IgG levels were diminished in anti-CD137 mAb-
treated mice beginning at 28 days post-immunization (Fig 3.2E). In NP-Ficoll-immunized mice, 
the number of NP-specific LLPCs at day 130 and NP-specific IgM+ MBCs at day 30 were 
equivalent between anti-CD137 and isotype control mAb-treated groups (Fig 3.2G-H), and 
serum anti-NP IgM and IgG levels generally were similar whether animals received anti-CD137 
or not (Fig 3.2I-J). Thus, anti-CD137 treatment impacts B cell responses that require T cell-
dependent help.  
Apoptosis and proliferation of GC B cells are minimally affected by anti-CD137 
mAb treatment. As reductions in GC B cells associated with anti-CD137 mAb treatment might 
be due to increased cell death, we stained GC B cells with annexin V, which recognizes 
phosphatidylserine on the plasma membrane of apoptotic cells. In this experiment, CHIKV-
infected mice were treated with anti-CD137 mAb at 2 dpi. The total number of CD86hiCXCR4lo 
light zone and CD86loCXCR4hi dark zone B cells were reduced slightly at 5 dpi (1.7-fold, P < 
0.01; 1.5-fold, P < 0.01, respectively) but more so at 7 dpi (2.2-fold, P < 0.0001; 5.8-fold, P < 
0.0001, respectively) in anti-CD137 mAb-treated mice compared to isotype control mAb-treated 
animals (Fig 3.3A-C). However, the percentage of annexin V+ Viability dye- early-stage 
apoptotic GC B cells in light or dark zone was similar between anti-CD137 and isotype control 
mAb-treated animals (Fig 3.3D, E and G). Anti-CD137 mAb treatment also did not alter the 
percentage of annexin V+ Viability dye+ late-stage apoptotic/necrotic GC B cells in the light or 
dark zones (Fig 3.3F and H). Thus, anti-CD137 mAb treatment does not appear to cause GC B 
cell deficits by promoting cell death. 
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To determine the effect of anti-CD137 treatment on GC B cell proliferation, we injected 
5-bromo-2'-deoxyuridine (Brdu) into CHIKV-infected mice and measured incorporation by GC 
B cells. The percentage of Brdu+ proliferating GC B cells was similar between animals treated 
with anti-CD137 and isotype control mAb except for small differences at 4 and 5 dpi (Fig 3.3I-
K). We also assessed whether there was any bias towards reducing the percentage of antigen-
specific GC B cells by incubating cells with chikungunya virus-like particles (CHIK VLP). The 
percentage of CHIKV-specific GC B cells was comparable between anti-CD137 mAb-treated 
and isotype control mAb-treated mice except for small differences at 5 dpi (Fig 3.4A-B). 
Anti-CD137 mAb treatment alters B cell follicle architecture. To examine whether 
anti-CD137 mAb affects the anatomic structures of the spleen, we performed 
immunofluorescence staining at 6 (Fig 3.5A-D), 7 (Fig 3.5E-F) and 14 (Fig 3.5I) dpi. At 6 dpi, 
we observed IgD+ B cells surrounding CD21/35+ FDCs, and some IgD+ B cells at the border of 
the CCL21+ T cell zone in isotype control mAb-treated mice (Fig 3.5A-B). However, in anti-
CD137 mAb-treated animals, the localization of IgD+ B cells at the T cell zone border was 
altered (Fig 3.5C-D). At 7 dpi, IgD+ B cells surrounded FDCs in the light zone in isotype control 
mAb-treated mice (Fig 3.5E), whereas in anti-CD137 mAb-treated animals, IgD+ B cells 
covered the FDC area (Fig 3.5F).  
We next determined whether anti-CD137 mAb treatment altered the number of FDCs in 
the spleen. Flow cytometry analysis revealed that in anti-CD137 mAb-treated mice the number 
of FDCs was comparable at 7 dpi but reduced at 14 dpi (17-fold, P < 0.0001; Fig 3.5G-H). 
Immunofluorescence microscopy confirmed that at 14 dpi the numbers of FDCs and GC B cells 
were decreased and/or dispersed in anti-CD137 mAb-treated mice compared to isotype control 
mAb-treated animals (Fig 3.5I-L). 
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Anti-CD137 mAb inhibition of GC formation requires T cell-intrinsic signaling. We 
first evaluated a possible role of CD137 signaling on stromal cells including FDCs, by 
transplanting WT or CD137-/- bone marrow into irradiated CD137-/- mice (Fig 3.6A) and 
confirming reconstitution (Fig 3.6B). Anti-CD137 mAb treatment reduced the number of GC B 
cells in mice receiving WT but not CD137-/- bone marrow (Fig 3.6C). For the reciprocal 
experiment, TCRβδ-/- mice were used as recipients because some T cell subsets (e.g., NKT and 
memory T cells) in WT recipients are radio-resistant (Yao et al., 2011), and we wanted to deplete 
endogenous T cells completely (Fig 3.6D). Anti-CD137 mAb treatment reduced the number of 
GC B cells in TCRβδ-/- mice receiving WT but not CD137-/- bone marrow (Fig 3.6E). These 
experiments suggest that CD137-mediated signaling in radio-sensitive, hematopoietic cells is 
required to reduce the number of GC B cells. 
To test whether anti-CD137 mAb treatment reduced the number of GC B cells through 
CD137 signaling in T cells, we adoptively transferred into recipient TCRβδ-/- mice combinations 
of CD4+ and CD8+ T cells isolated from WT or CD137-/- mice (Fig 3.6F). Anti-CD137 mAb 
treatment reduced the number of GC B cells in mice receiving WT CD4+ T cells + WT CD8+ T 
cells, CD137-/- CD4+ T cells + WT CD8+ T cells, or WT CD4+ T cells + CD137-/- CD8+ T cells 
(15.0 to 20.5-fold, P < 0.001), but not in mice receiving CD137-/- CD4+ + CD137-/- CD8+ T cells 
(Fig 3.6G). Thus, CD137-mediated signaling in either CD4+ or CD8+ T cells is sufficient to 
inhibit GC B cell production. 
Anti-CD137 mAb treatment promotes pro-inflammatory signatures in cycling CD8+ 
T cells, neutrophils, and differentiating monocytes. To define global transcriptional changes 
in lymphoid tissues of mice treated with anti-CD137 mAb, we performed single cell RNA 
sequencing (scRNAseq) on splenocytes harvested from CHIKV-infected mice during the acute 
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phase of infection (3 and 7 dpi). Immune cell subsets were identified by their cell type-specific 
gene expression: CD3e (T cells), Ncr1 (NK cells), CD79a (B cells), Flt3 (DCs), Sdc1 
(plasmablasts), Adgre1 (macrophages), S100a8 (neutrophils), and Ccr2/Ly6c2 (monocytes) (Fig 
3.7A). 
The majority of cells expressing Tnfrsf9, the gene encoding CD137, were NK and T cells 
(Fig 3.7B), which were re-clustered to identify different cell subsets (e.g. NK cells, NKT cells, 
CD4+ and CD8+ T cells, and activated T cells) (Fig 3.7C-D). Among activated T cells, the 
frequency of cycling CD8+ T cells, characterized by expression of Ccnb2, Ccna2, Cdca3 and 
Mki67 (Fig 3.8A), was increased in anti-CD137 mAb-treated mice compared to isotype control 
mAb-treated animals at 7 dpi. The cycling CD8+ T cells and NK cells showed a pro-
inflammatory and cytolytic signature with high transcript levels of Gzma, Gzmb and Ccl5 (Fig 
3.8B). The cycling CD8+ T cells uniquely expressed Gzmk (Fig 3.8C). We also observed 
expansion of myeloid cell subsets with pro-inflammatory signatures in anti-CD137 mAb-treated 
mice. For example, the chemokine receptors Ccrl2, Ccr1 and Cxcr2 and Ly6i were expressed in 
the subset of S100a8/Mmp9-expressing neutrophils (Fig 3.9A-F) at higher levels at 7 dpi in anti-
CD137 mAb treated mice; these cells also expressed Cxcl2, Il1b, Ccl6, Csf1, Tnf, Tnfsf14, and 
Il15 (Fig 3.9G-H). This neutrophil subset also expressed Irg1, which produces itaconate, a 
regulator of immune cell metabolism and inflammation (Lampropoulou et al., 2016) (Fig 3.9I-J). 
Monocytes were identified by expression of Ccr2 and Ly6c2 (Fig 3.7A and S4A). Clustered with 
the Ccr2-expressing monocytes were differentiating monocytes expressing Spic, a marker of red 
pulp macrophages (Fig 3.10B-C). Heme moieties released from senescent or damaged 
erythrocytes can induce Spic expression in differentiating monocytes (Haldar et al., 2014), and 
Hba-a1, Rhd and Tfrc expressing reticulocytes were transiently depleted at 3 dpi, which 
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correlated with Spic induction in the monocytes (Fig 3.10D). Differentiating monocytes persisted 
in anti-CD137 but not isotype control mAb-treated mice at 7 dpi and expressed higher levels of 
Cxcl10, Cxcl9, Ccl2, Cxcl16 and Ccr5 (Fig 3.10E-H). Thus, scRNAseq analysis revealed 
expansion of several lymphoid and myeloid cell populations with pro-inflammatory signatures in 
anti-CD137 mAb-treated mice. 
Anti-CD137 mAb treatment alters the number of follicular helper, regulatory, and 
follicular regulatory T cells. scRNAseq analysis revealed an activated CD4+ T cell subset 
expressing genes (Cxcr5 and Il21) characteristic of follicular helper T (Tfh) cells (Fig 3.11A) 
(Kuchen et al., 2007). Both RNAseq and flow cytometric data showed that at 7 dpi anti-CD137 
mAb treatment resulted in a reduced frequency and number of CXCR5hiPD-1hi Tfh cells (2.1-
fold, P < 0.0001) (Fig 3.11B-C); these T cells provide pro-survival and differentiation signals to 
GC B cells (Baumjohann et al., 2013). We assessed whether the decreased number of Tfh cells in 
anti-CD137 mAb-treated mice was linked to the reduction of GC B cells. We administered IL-2-
depleting and CTLA-4-blocking mAbs: IL-2 regulates Tfh cell differentiation by negatively 
modulating Bcl6 expression (Ballesteros-Tato et al., 2012), and CTLA-4 regulates Tfh cell 
differentiation by controlling the strength of CD28 signaling (Wang et al., 2015). Combination 
treatment with IL-2-depleting and CTLA-4-blocking mAbs increased the number of Tfh cells in 
mice treated with anti-CD137 mAb to levels similar to those treated with isotype control mAb 
without treatment (Fig 3.11D). However, this treatment did not restore the number of GC B cells 
in anti-CD137 mAb treated mice (Fig 3.11E). Thus, anti-CD137 mAb-mediated reduction in GC 
B cells did not require reductions in Tfh cells. 
By scRNAseq analysis, anti-CD137 mAb treatment increased the proportion of CD4+ and 
CD8+ T cells expressing Foxp3 (Fig 3.12A-C). FoxP3 reportedly increases the expression of 
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Tnfrsf9 (Marson et al., 2007). Flow cytometric analysis showed that the majority of CD4+ T cells 
expressing CD137 also expressed FoxP3 at 2 dpi (Fig 3.12D). Anti-CD137 mAb treatment 
increased the number and frequency of CD4+FoxP3+ Tregs (Fig 3.12E-G), CD4+CXCR5hiPD-
1hiFoxP3+ T follicular regulatory cells (Tfr) (Fig 3.12H-I), and CD8+FoxP3+ T cells (Fig 3.12J-
K). Because Tfr cells can modulate GC responses (Linterman et al., 2011), we used an adoptive 
transfer approach to assess whether the increased number of Tfr cells in anti-CD137 mAb-treated 
mice caused the reduction in GC B cells. T cells from CD137-/- mice and FoxP3+ T cells sorted 
from FoxP3-GFP reporter mice were mixed and transferred into recipient TCRβδ-/- mice (Fig 
3.12L). Although Treg and Tfr cells were reconstituted in recipient mice (Fig 3.12M), anti-
CD137 mAb treatment failed to reduce the number of GC B cells at 14 dpi (Fig 3.12N). Thus, 
CD137 signaling exclusively on Treg and Tfr cells was not sufficient for anti-CD137 mAb-
mediated reduction of GC B cells. 
Anti-CD137 mAb reduces the GC B cell population defined by transcriptional 
signature. B cells were re-clustered to identify different cell subsets (e.g. follicular B cells, MZ 
B cells, plasmablasts, cycling B cells) (Fig 3.7C-D). Myc is expressed transiently in GC B 
precursors and establishes a cyclin D2-dependent proliferation program (Calado et al., 2012). 
Single cell analysis indicated that Myc-induced gene targets were expressed equivalently 
between anti-CD137 and isotype control mAb-treated animals (Fig 3.13A), suggesting that the 
Myc-dependent program in initiating GC precursors is not altered by anti-CD137 mAb 
treatment. Some of the B cell subsets were cycling based on expression of Cdc6, Cdc45, Cdc123, 
Cdc20, Cdc25b, Cdc37 and Mki67 (Fig 3.13B). A subset of the cycling B cells expressed Ezh2 
and Dnmt1, which silence genes inhibiting proliferation (Shaknovich et al., 2011; Velichutina et 
al., 2010) (Fig 3.13C). In this subset, we observed cells expressing S1pr2 and Aicda, markers of 
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GC B cells (Fig 3.13D-E). Consistent with flow cytometry data (Fig 3.1D), single cell RNAseq 
analysis showed a lower fraction of cells with a GC B cell transcriptional signature in anti-
CD137 mAb-treated animals (Fig 3.13F). Because CCR7 facilitates B cell migration and 
interaction with cognate T cells prior to the formation of GCs (Okada et al., 2005), we evaluated 
effects of anti-CD137 mAb treatment on Ccr7 expression in B cells. The frequency of B cells 
expressing Ccr7 was reduced in anti-CD137 mAb-treated mice compared to isotype control 
mAb-treated animals at 7 dpi (Fig 3.13G).  
Anti-CD137 mAb treatment reduces the number of MZ B cells and their expression of 
CD21/35. The frequency of MZ B cells, characterized by expression of Cd9, Dtx1, Fcrl5 and 
Cr2, was increased in both anti-CD137 and isotype-control mAb-treated mice at 3 dpi compared 
to naïve animals (Fig 3.14A). MZ B cell development requires Notch-RBP-J signaling (Tanigaki 
et al., 2002). At 7 dpi, the frequency of cells showing high expression levels of Notch signaling 
target genes (e.g., Dtx1 (Deltex-1, regulator of Notch signaling) and Cr2 (Complement receptor 
2)) in MZ B cells of anti-CD137 mAb-treated mice was less than in isotype control mAb-treated 
animals (Fig 3.14B). Consistently, flow cytometric analysis showed that anti-CD137 mAb 
treatment reduced the number of MZ B cells (2.0-fold, P < 0.05), but not follicular B cells at 7 
dpi (Fig 3.14C-E). By 14 dpi, the numbers of both follicular and MZ B cells were reduced in 
anti-CD137 mAb treated mice compared to isotype control mAb treated animals (1.9-fold, P < 
0.01; 3.7-fold, P < 0.01, respectively). B cell expression of CD21 and CD35, which encode for 
complement receptors, is critical for GC formation and response to T cell-dependent antigens 
(Carroll, 1998). Both follicular and MZ B cells showed reduced expression of CD21/CD35 at 7 
dpi (1.8-fold, P < 0.0001; 1.7-fold, P < 0.0001, respectively) (Fig 3.14F). 
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Anti-CD137 mAb treatment increases the number of antigen non-specific plasmablasts 
and minimally alters BCR usage. Transcriptional analysis suggested that plasmablasts genes 
(Xbp1, Irf4 and Prdm1) were more abundant in anti-CD137 and isotype mAb-treated mice at 7 
dpi compared to naïve animals, but more so in anti-CD137 mAb-treated animals (Fig 3.14G-H). 
Indeed, flow cytometry of splenocytes showed that in anti-CD137 mAb-treated mice the total 
number of plasmablasts was increased at 7 dpi (2.1-fold, P ≤ 0.05) but reduced at 14 dpi (2.9-
fold, P ≤ 0.01) (Fig 3.14I-J). In naïve mice, anti-CD137 mAb treatment did not alter the number 
of plasmablasts in the spleen (Fig 3.14K). 
Antigen binding by BCR and subsequent signaling promotes differentiation of B cell 
subsets. During a primary GC reaction, germline B cells that bind to antigens undergo somatic 
hypermutation and clonal selection, which biases the usage of particular BCR genes in the pool 
of responding cells (Kuraoka et al., 2016). We evaluated whether anti-CD137 mAb treatment 
altered VDJ recombination and clonality of B cells by analyzing the scRNAseq data at 0 and 7 
dpi. Overall, the BCR gene usage was similar between anti-CD137 mAb- and isotype control 
mAb-treated mice. Among the IgG clonotypes, Igh2c was dominantly used (Fig 3.15A-C). There 
was bias in usage of Ighv1-80 heavy chains joined with Igkv5-39 and Igkv5-43 light chains in 
both anti-CD137 and isotype control mAb-treated CHIKV-infected mice, but not in naïve 
animals (Fig 3.15A), suggesting that these genes were selected during acute infection. There 
were minimal differences in V-gene usage of lambda light chains or J gene usage among anti-
CD137 and isotype control mAb-treated CHIKV-infected mice and naïve animals (Fig 3.15A-
B). Thus, the BCR usage seems minimally altered by anti-CD137 mAb treatment. 
Even though there was an expansion of plasmablasts in anti-CD137 mAb-treated mice 
compared to isotype control mAb-treated animals, this did not occur at a clonal level (Fig 
59	
	
3.15C). The number of CHIKV-specific plasmablasts was similar between anti-CD137 mAb- 
and isotype control mAb-treated mice (Fig 3.14L). Thus, it appears that B cells with low or no 
affinity for CHIKV antigens prematurely differentiated into plasmablasts in anti-CD137 mAb-
treated animals. 
Anti-CD137 mAb-mediated increase in plasmablasts is abrogated by a type 2 
immune response. At early stages of the immune response, B cells can differentiate into 
plasmablasts through T cell-dependent or -independent programs (Saito et al., 2007). We tested 
whether the expansion of plasmablasts in the anti-CD137 mAb-treated mice required CD40L 
interaction on T cells using a blocking mAb. Anti-CD137 mAb treatment increased the number 
of plasmablasts regardless of whether anti-CD40L blocking mAb was administered (Fig 3.14M), 
suggesting that anti-CD137 mAb treatment results in expansion of early plasmablast 
compartment in the spleen at 7 dpi through a pathway that at least is partially independent of 
CD40/CD40L signaling.  
Because anti-CD137 mAb treatment drives a type 1, pro-inflammatory immune response 
(Sun et al., 2002), we tested whether skewing towards a type 2 immune response program would 
reverse the plasmablast phenotype. Indeed, the number of plasmablasts was not increased in 
mice given anti-CD137 mAb and the IL-4-anti-IL-4 antibody complexes (Reese et al., 2014) 
(Fig 3.14N). Thus, the type 1 immune response induced by anti-CD137 mAb that is disrupted by 
exogenous IL-4 treatment appears to contribute the expanded number of plasmablasts after 
CHIKV infection. 
Anti-CD137 mAb treatment effects on GC B cells, antigen-specific MBCs, and 
antigen-specific plasmablasts in the context of viral vaccine immunization or boosting. Tfh 
and FDCs within secondary lymphoid follicles promote rapid activation and differentiation of 
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MBCs upon antigen re-encounter. Since we observed that anti-CD137 mAb treatment disrupted 
secondary lymphoid follicles, and given its possible use in humans, we tested its effect on an 
anamnestic response to a vaccine. Influenza virus hemagglutinin is a well-defined antigen that 
elicits neutralizing antibodies (Impagliazzo et al., 2015). Nine-week-old C57BL/6 female mice 
were injected via intramuscular route with influenza A virus H5 hemagglutinin proteins (day 0) 
and then injected i.p. with anti-CD137 mAb at 2 days post-immunization (Fig 3.16A). At 28 
days post-immunization, the mice were boosted with a second dose of H5 protein. The number 
of GC B cells, antigen-specific MBCs and plasmablasts were reduced in anti-CD137 mAb-
treated mice compared to isotype control mAb-treated animals 7 days after secondary boosting 
(11.6-fold, P < 0.001; 30.5-fold, P < 0.001; 281-fold, P < 0.001, respectively) (Fig 3.16B-D). In 
another group of mice, we administered anti-CD137 mAb the day prior to boosting to assess for 
effects of anti-CD137 mAb treatment on the anamnestic B cell response (Fig 3.16E). The 
numbers of GC B cells and antigen-specific MBCs but not antigen-specific plasmablasts were 
reduced in anti-CD137 mAb-treated mice compared to isotype control mAb-treated animals 7 
days after boosting (12.9-fold, P < 0.001; 7.1-fold, P < 0.001; and not significant, respectively) 
(Fig 3.16F-H). Thus, during an anamnestic memory response, anti-CD137 mAb treatment 
affects the secondary GC B cell and MBC response while having a minimal effect on 









In this study, we have shown that administration of anti-CD137 mAb early (day 2) but 
not late (day 56) after CHIKV infection dampens the durable humoral immune response as 
judged by marked reductions in antigen-specific MBCs, LLPCs, and serum antibody titers. 
Similarly, long-lasting antibody responses were impaired in response to NP-KLH, a T cell-
dependent antigen, but not NP-Ficoll, a T cell-independent antigen. The inhibition of GC 
formation in anti-CD137 mAb-treated mice was not associated with increased cell death or 
decreased proliferation of GC B cells but correlated with a disorganized architecture of the B cell 
follicle. The anti-CD137 mAb-mediated inhibition of GC B cells required CD137 signaling on 
either CD4+ or CD8+ T cells. In addition to its effects on GC formation, anti-CD137 mAb 
treatment also reduced the number of MZ B cells and increased the number of antigen non-
specific plasmablasts, which was reversed by IL-4-anti-IL-4 complex treatment. Administration 
of anti-CD137 mAb prior to boosting with an influenza virus hemagglutinin protein antigen 
reduced the secondary GC reaction but did not affect the differentiation of antigen-specific 
plasmablasts. 
GCs are dynamic structures where antigen-specific B cells activated by cognate T cells 
ingress and egress. Upon antigen engagement, CCR7-expressing B cells migrate to the borders 
of T cell zones where they interact with cognate T cells before forming GCs (Okada et al., 2005). 
We observed that the frequency of Ccr7-expressing B cell subset was reduced in anti-CD137 
mAb-treated mice. This was consistent with imaging experiments where we observed an altered 
pattern of cells at the B cell-T cell border. During GC reaction, expansion and maintenance of 
GC B cells requires cognate help from Tfh cells and input from stromal cells including FDCs 
that reside within lymphoid follicles (Endres et al., 1999). Our observations describing a 
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disrupted B cell follicular architecture are consistent with an earlier report, which showed that 
anti-CD137 mAb treatment diminished GC formation and FDC networks, although that study 
was limited to immunohistochemistry analysis up to 14 days after immunization with sheep red 
blood cells and KLH (Sun et al., 2005). Because the proportion of GC B cells undergoing 
apoptosis or proliferation was similar between anti-CD137 and isotype control mAb-treated 
mice, we hypothesize that the inflammatory environment induced by anti-CD137 mAb-activated 
T cells resulted in improper GC B cell priming due to altered architecture, which in turn resulted 
in GC collapse and dispersal of activated B cells. 
V(D)J recombination establishes a diverse BCR repertoire, and subsequent somatic 
hypermutation and class switching after antigen encounter promote affinity maturation and 
effector function differentiation. In anti-CD137 mAb-treated infected mice, some B cells with 
low or no affinity for viral antigens may differentiate prematurely into plasmablasts. Indeed, we 
observed comparable numbers of CHIKV-specific plasmablasts in anti-CD137 and isotype 
control mAb-treated mice, even though the total number of plasmablasts was increased in anti-
CD137 mAb-treated animals. Although anti-CD137 mAb treatment resulted in the expansion of 
the early plasmablast response, the inhibition of the GC reaction led to dampened long-term 
antigen-specific antibody responses. 
Anti-CD137 mAb when given at 2 days after the first immunization of influenza 
hemagglutinin protein globally impaired anamnestic B cell responses at 7 days after the 
secondary booster immunization. However, when anti-CD137 mAb was given the day before 
secondary boosting, the number of antigen-specific plasmablasts was not reduced, suggesting 
that this response does not require a secondary GC reaction. After primary immunization, 
CXCR5-expressing memory Tfh cells accumulate at the B cell-T cell border and mediate 
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efficient recall antibody responses (Aiba et al., 2010; MacLeod et al., 2011). Upon encountering 
specific antigens during secondary infection or immunization, MBCs present antigen to cognate 
CD4+ T cells and proliferate and differentiate rapidly into plasmablasts (Aiba et al., 2010; 
Kurosaki et al., 2015). Thus, when given prior to boosting, anti-CD137 mAb likely does not 
affect interaction between MBCs and cognate memory Tfh cells. In contrast, anti-CD137 mAb 
likely hinders the secondary GC reaction of pre-existing MBCs. During the recall response, 
exogenous antigens bound by antibodies may be transported to FDCs, which then present 
immune complexes to MBCs for further rounds of affinity maturation and LLPC differentiation 
(Hanna and Szakal, 1968). Since mice treated with anti-CD137 mAb show perturbed GC 
architecture, secondary MBC differentiation likely becomes compromised. 
Although agonistic anti-CD137 mAb are being considered as treatments for cancer and 
autoimmune diseases (Foell et al., 2003; Mittler et al., 2004; Yonezawa et al., 2015), their 
mechanism(s) of action remain unclear, and possible collateral effects on immune responses are 
understudied. Ligation of CD137 in DCs was reported to enhance expression of retinal 
dehydrogenase, which induces differentiation of FoxP3+ regulatory T cells (Lee et al., 2012). In a 
mouse model of collagen type II-induced arthritis, anti-CD137 mAb treatment induced 
expansion of CD11c+CD8+ T cells that produced IFNγ, which in turn induced tolerogenic DCs 
(Seo et al., 2004). Here, we showed that agonistic anti-CD137 mAb treatment inhibited humoral 
and cellular B cell responses, which could be another explanation for its utility in autoimmunity. 
Our data establish that T-cell-intrinsic signaling is required for CD137-dependent reduction in 
GC formation. This conclusion is consistent with a prior study showing that anti-CD137 mAb 
treatment diminished FDC networks in WT but not T cell-deficient mice (Sun et al., 2005). 
While the precise mechanism by which CD4+ and CD8+ T cells damage the FDC network 
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remains to be elucidated, our study establishes how anti-CD137 mAb compromises induction of 
memory responses in the B cell compartment. Although a corroborating analysis of human 
subjects is warranted, anti-CD137 mAb treatment in the context of immunotherapy could 







Viruses and cells. The recombinant CHIKV La Reunion OPY1 strain was generated 
from in vitro transcribed cDNA as described previously (Tsetsarkin et al., 2006). The resultant 
virus was propagated once in C6/36 Aedes albopictus cells and titrated using Vero cells and a 
focus-forming assay as described (Pal et al., 2013).  
Animal studies. All animal experiments were performed with the approval of 
Washington University Institutional Animal Care and Use Committee guidelines. All mouse 
infection studies were performed in an animal biosafety level 3 laboratory. C57BL/6J (000664), 
B6.129P2-Tcrbtm1Mom Tcrdtm1Mom/J (002121; abbreviated TCRβδ-/-), C.Cg-Foxp3tm2Tch/J (006769; 
abbreviated FoxP3-GFP) and B6.SJL-Ptprca Pepcb/BoyJ (002014) were purchased from Jackson 
Laboratories. CD137-/- mice (Kwon et al., 2002) were obtained as a gift from Michael Croft (La 
Jolla Institute for Immunology). At 4 weeks of age, male mice were anesthetized with ketamine 
hydrochloride (80 mg/kg) and xylazine (15 mg/kg) and inoculated s.c. in the left rear footpad 
with 103 focus-forming units (FFU) of CHIKV in 10 µl of PBS. For immunization with NP-
Ficoll (Biosearch Technologies) or NP-KLH (Biosearch Technologies), 4-week-old C57BL/6J 
male mice were injected via i.p. route with 5 µg of NP-Ficoll in 200 µl of PBS or 10 µg of NP-
KLH in 100 µL of alum mixture (1:1 ratio of immunogen in PBS to alum (Thermo)). For 
administration of IL-4-anti-IL-4 antibody complexes, 5 µg of recombinant murine IL-4 
(Peprotech) and 25 µg of anti-IL4 mAb (clone 11B11, Bioxcell) were mixed in 100 µl of PBS at 
4°C for 30 min before injection. For immunization with influenza A virus H5 hemagglutinin, 9-
week-old C57BL/6J female mice were injected via intramuscular (i.m.) route with 10 µg of 
recombinant H5 HA (Ellebedy et al., 2014) in 50 µL of antigen:AddaVax (1:1) (InvivoGen). At 
the termination of experiments, mice were euthanized and perfused via intracardiac injection 
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with PBS. For proliferation assays, CHIKV-infected mice were injected via intravascular route 
with 1 mg of Brdu in 100 µL of PBS two hours before harvest. 
Antibodies and cell depletions. Anti-CD137 mAb (clone 2A, rat Ig2a) has been 
described previously (Wilcox et al., 2002b). Ab was purified from hybridoma supernatants by 
protein G affinity chromatography by a commercial vendor (BioXCell). Anti-IL-2 (clone S4B6-
1), anti-CTLA-4 (clone 9D9), anti-CD40L (clone MR-1), mouse IgG2a (clone 2A3) and mouse 
IgG2b (clone MPC-11) served as controls for IL-2 depletion and CTLA-4 blockade, respectively. 
Polyclonal Armenian hamster IgG was used a control for CD40L blockade and purchased from 
BioXCell. Mice were administered 400 µg of anti-CD137 or rat Ig2a isotype control mAb (clone 
2A3, BioXCell) via i.p. route at 2 dpi. For IL-2 depletion studies, mice were administered 500 µg 
of anti-IL-2 mAb on 2, 4 and 6 dpi. For CTLA-4 blockade, mice were administered 500 µg of 
anti-CTLA-4 mAb on 2 dpi and 250 µg on 5 dpi. For CD40L blocking experiments, mice were 
administered 500 µg of anti-CD40L mAb on 2 dpi and every 3 days thereafter until 7 dpi. 
Immune cell analysis. Spleens were minced and incubated for 30 min at 37oC in 2 ml 
digestion buffer (1 mg/ml collagenase (Sigma) and 100 mg/mL DNase I (Sigma) in Dulbecco’s 
Modified Eagle’s medium (DMEM) containing 2% FBS in a 24-well plate. Cell suspensions 
were passed through a 100 µm cell strainer. After rinsing with 10% FBS, 5 mM EDTA in 
DMEM, erythrocytes were lysed with 1 mL of ACK Lysing Buffer (Gibco) per spleen for 2 min. 
Cells were washed with DMEM and centrifuged, followed by rinsing with washing buffer (2% 
FBS, 5 mM EDTA in PBS). After centrifugation, cells were resuspended in washing buffer at 5 x 
108 cells/ml and incubated with 2.5 mg of anti-mouse CD16/32 antibody (101302, Biolegend) 
per 108 cells for 20 min on ice. Then, cells were stained with BV605-conjugated anti-CD45 
(103140, Biolegend), PE-Cy7-conjugated anti-CD3 (100320, Biolegend), APC-Cy7-conjugated 
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anti-CD19 (115530, Biolegend), FITC-conjugated anti-CD21/35 (553818, BD Biosciences), PE-
conjugated anti-CD95 (554258, BD Biosciences), Alexa647-conjugated anti-FoxP3 (126408, 
Biolegend), biotinylated anti-CXCR5 (145510, BIolegend), BV421-conjugated anti-CD4 
(100438, Biolegend), PerCP/Cy5.5-conjugated anti-CD8α (100734, Biolegend), Alexa647-
conjugated anti-CD86 (105019, Biolegend), PE-conjugated anti-CXCR4 (146505, Biolegend), 
FITC-conjugated anti-PD-1 (135214, Biolegend), BV510-conjugated anti-CD45.1 (110741, 
Biolegend), Alexa700-conjugated anti-CD45.2 (56-0454-82, eBioscience), PE-conjugated anti-
CD23 (101608, Biolegend), Alexa647-conjugated anti-CD138 (142526, Biolegend), BV421-
conjugated anti-TACI (742840, BD Biosciences), biotinylated anti-IgG (B7022, Sigma), BV421-
conjugated anti-IgM (406517, Biolegend), Alexa647-conjugated anti-CD38 (102716, 
Biolegend), BV510-conjugated anti-IgD (405723, Biolegend), PerCP/Cy5.5-conjugated anti-
GL7 (144609, Biolegend) antibody, biotinylated PNA (B-1075, Vector), Alexa647-conjugated 
streptavidin (S32357, Invitrogen) and eFluor506 fixable viability dye (65-0866-14, eBioscience). 
For detection of apoptosis, an annexin V detection kit eFluor450 (88-8006-72, eBioscience) was 
used according to the manufacturer’s instructions. For proliferation detection, the Brdu flow kit 
(559619, BD) was used according to the manufacturer’s instructions. To confirm CD137 
expression, cells were stained with biotinylated anti-CD137 (106104, Biolegend). For detection 
of NP-specific and hemaglutinin-specific memory B cells, cells were stained sequentially with 
PE-conjugated NP (N-5070-1, LGC Biosearch Technologies) or biotinylated H5 (IT-003-
0052ΔTMp, Immune Technology). Subsequently, cells were fixed with BD FACS Lysing 
Solution, processed on a LSR Fortessa X-20 (BD Biosciences) flow cytometer, and analyzed 
using BD FACSDiva and FlowJo software. 
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Single cell RNA sequencing. Isolated single cell suspensions were subjected to droplet-
based massively parallel single cell RNA sequencing using Chromium Single Cell 5’ Reagent 
Kit in a BSL-3 level laboratory as per manufacturer’s instructions (10x Genomics). Briefly, cell 
suspensions were loaded at 1,000 cells/µL with the aim to capture 10,000 cells/well. The 10x 
Chromium Controller generated GEM droplets, where each cell was labeled with a specific 
barcode, and each transcript labeled with a unique molecular identifier (UMI) during reverse 
transcription. The barcoded cDNA was isolated via a Dynabeads MyOne SILANE bead cleanup 
mixture and amplified 13 cycles. Amplified cDNA was purified via SPRI bead cleanup and 
removed from the BSL-3 space for library generation.  For gene expression libraries, 50 ng 
of amplified cDNA was used for library preparation, consisting of fragmentation, end repair, A-
tailing, adapter ligation and sample index PCR as per the manufacturer’s instructions. Libraries 
were sequenced on a NovaSeq S4 (200 cycle) flow cell, targeting 45,000 read pairs/cell. For B 
Cell repertoire libraries, 2 µl of amplified cDNA underwent two rounds of Target Enrichment 
using nested primer pairs specific for mouse B cell Ig constant regions. 50 ng of the target 
enrichment PCR product was used for library preparation, consisting of fragmentation, end 
repair, A-tailing, adapter ligation and sample index PCR as per the manufacturer’s instructions. 
Enriched libraries were sequenced on a NovaSeq S4 (200 cycle) flow cell, targeting 5,000 read 
pairs/cell. All sequencing data have been submitted to the GEO database (GSE accession number 
assignment pending). 
scRNAseq analysis. Sample demultiplexing, barcode processing, and single-cell 5’ 
counting was performed using the Cell Ranger Single-Cell Software Suite (10x Genomics). 
Cellranger count was used to align samples to the mm10 reference genome, quantify reads, and 
filter reads with a quality score below 30. The resultant files were input into Seurat for 
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normalization across all samples and merging. The Seurat package in R was used for subsequent 
analysis (Butler et al., 2018). Cells with mitochondrial content greater than 5 percent were 
removed for downstream analysis. Data were normalized using a scaling factor of 10,000, and 
number of Unique Molecular Identifiers was regressed with a negative binomial model. Principal 
component analysis was performed using the top 3,000 most variable genes and t-SNE analysis 
was performed with the top 10 PCAs. Clustering was performed using the FindClusters function 
which works on K-nearest neighbor graph model with the granularity ranging from 0.1-0.9 and 
selected 0.6 for the downstream clustering. For identifying the markers for each cluster, we 
performed differential expression of each cluster against all other clusters identifying negative 
and positive markers for that cluster. Nuclei from different cell types (e.g., NK cells/T cells and 
B cells) were re-clustered to further analyze transcripts in each cell type. 
B cell clonal analysis. The sequencing reads were preprocessed using 10X Genomics' 
cellranger vdj package. The B cell receptor (BCR) sequences were assembled using the mouse 
IMGT database and variable V, J, and constant chain alleles were called for both heavy and light 
chain. BCRs with identical CDR3 nucleotide sequences were assigned to the same clonal family 
irrespective of their V, J, and constant region calls, which are the standard parameters. Among 
all sequenced cells, B cells were identified by transcriptome analysis. Briefly, reads were 
mapped against the Mus musculus genome (mm10-3.0.0) using cellranger count, which included 
STAR aligner (Dobin et al., 2013) and HTSeq (Anders et al., 2015). The gene expression table 
was restricted to the 500 genes with the highest Fano factor and log transformed. PCA with 30 
components was then used to reduce dimensionality, pairwise correlation distances were then 
used to construct a k-nearest neighbor graph with k=15 and a threshold for edge calling of ≥0.2. 
Unsupervised clustering on the graph was performed using Leiden (Traag et al., 2019), constant 
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Potts model optimization, and a resolution parameter of 0.001. Clonal analysis was performed 
for heavy and light chains separately. Clonal graph plots were restricted to families with ≥2 
members. All plots were generated via custom Python 3.7 scripts. The code for the whole B cell 
clonal analysis is available at https://github.com/iosonofabio/BCR_Zanini_Diamond. 
Immunofluorescence imaging. Spleens were fixed in periodate-lysine-
paraformaldehyde buffer for 48 h, and moved to 30% sucrose in PBS for at least 24 h before 
embedding. Tissues were embedded in optimal-cutting-temperature medium (Electron 
Microscopy Sciences) in longitudinal orientation and frozen in dry-ice-cooled isopentane. 18-µm 
sections were cut on a Lecia cryostat (Leica Microsystems), blocked with 10% bovine and 
donkey serum, and then stained with combinations of the following antibodies: anti-ERTR7 
(51824, Abcam), anti-CD21/35 (2033272, Invitrogen), anti-CD4 (ab183685, Abcam), Alexa555-
conjugated anti-rabbit IgG (A21428, Invitrogen), Alexa700-conjugated anti-B220 (103232, 
Biolegend), Alexa647-conjugated anti-GL7 (144606, Biolegend), Alexa647-conjugated anti-goat 
IgG (A21447, Invitrogen), biotinylated anti-IgD (1120-08, Southern Biotech) antibody and 
Alexa555-conjugated streptavidin (S32355, Invitrogen). Images were acquired on a Leica SP8 
confocal microscope equipped with acousto-optical tunable filters, HyD hybrid detectors, and a 
700 nm wavelength laser (Leica Microsystems). Images were merged from tilescans acquired 
with a 40X objective. Images were processed and analyzed using Imaris (Bitplane). FDC area 
was calculated using the “Surfaces” function of Imaris and measured only FDCs networks in 
follicles that contained FDCs. GC B cells were marked using the automated “Spots” function of 
Imaris. The percentage of GC B cells far away from FDCs were calculated using the Imaris XT 
module “Spots and Surfaces Distance.”  GC B cells were considered far away from FDCs if they 
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were greater than 10 µm from the closest FDC surface. The distance between GC B cells was 
calculated using the Imaris XT module “Spots to Spots Closest Distance.” 
Adoptive transfer experiments. Minced spleens from naïve WT or CD137-/- mice were 
passed through a 70 µm cell strainer to generate single cell splenocyte suspensions. After lysis of 
erythrocytes, CD4+ and CD8+ T cells were isolated using the CD4+ or CD8α+ T Cell Isolation 
Kits (130-104-454 and 130-104-075, respectively, Miltenyi Biotec) according to the 
manufacturer’s instructions. 4.3 x 106 CD4+ T cells and 2.8 x 106 CD8+ T cells were mixed and 
adoptively transferred into TCRβδ-/- mice. After 5 days, the recipient mice were inoculated with 
103 FFU of CHIKV. For adoptive transfer of FoxP3+ T cells, spleens from naïve CD137-/- mice 
and FoxP3-GFP reporter mice were processed as described above. T cells were isolated using the 
Pan T Cell Isolation Kit (130-090-130, Miltenyi Biotec). The isolated T cells were sorted using a 
BD FACS Aria II. 1.3 x 105 sorted FoxP3+ T cells and 7.1 x 106 CD137-/- T cells were adoptively 
transferred into TCRβδ-/- mice. 
ELISA. MaxiSorp 96-well flat-bottom ELISA plates (44-2404-21, Thermo) were coated 
with 2 µg/ml of CHIKV E2 protein (Pal et al., 2013) or 20 µg/ml of NP-conjugated chicken 
gamma globulin (NP-CGG, Biosearch Technologies) overnight at 4°C. Plates were washed with 
ELISA wash buffer (PBS, 0.05% Tween-20) and then incubated with blocking buffer (PBS, 5% 
FBS) for 4 h at 37°C. Sera from CHIKV-infected, NP-KLH- or NP-Ficoll-immunized mice were 
added in 3-fold dilutions starting with a 1/100 dilution. After incubating for 1 h at room 
temperature, plates were rinsed with ELISA wash buffer and then incubated with biotinylated 
anti-IgG (115-065-062, Jackson ImmunoResearch) for 1 h at room temperature. After washing, 
plates were incubated with streptavidin-conjugated HRP (SA-5004, Vector Laboratories) for 30 
min at room temperature. After final rinses with ELISA wash buffer and PBS, substrate solution 
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(34029, Thermo) was added. The reaction was quenched with 2N H2SO4, and the plates were 
read using a Synergy H1 Hybrid Reader (BioTek). The optical density (OD) value of naïve 
serum was subtracted from OD values of CHIKV-infected or NP-Ficoll- or NP-KLH-immunized 
samples, and non-linear regression curves were calculated. The titer of anti-CHIKV or anti-NP 
was defined as the dilution of serum yielding a half-maximal OD value after background and 
naïve value subtraction. 
MBC limiting dilution assay. 96-well flat-bottom feeder cell plates were seeded with 
BAFF- and CD40L-expressing feeder cells the day before B cell isolation and were incubated 
with 5 µg/ml of mitomycin C at 37°C and 5% humidified CO2 for 3 h, as described before 
(Purtha et al., 2011). Splenocyte suspensions from CHIKV-infected mice were centrifuged and 
resuspended in washing buffer (1% FBS, 2 mM EDTA in PBS). CD19+ B cells were isolated 
using CD19 MicroBeads (130-052-201, Miltenyi Biotec) according to the manufacturer’s 
protocol. The isolated B cells were cultured (RPMI, 10% FBS, 1X penicillin-streptomycin, 1 
mM sodium pyruvate, 0.1 mM non-essential amino acids, 10 mM HEPES, 50 µM β-
mercaptoethanol) in 5-fold dilutions starting at 1,000,000 cells per well in the feeder cell plates 
sealed with an adhesive film at 37°C and 5% humidified CO2 for 6 days. To calculate the 
frequency of CHIKV-specific MBCs that produced IgG, MaxiSorp 96-well flat-bottom ELISA 
plates (44-2404-21, Thermo) were coated with 2 µg/ml of CHIKV E2 protein (Pal et al., 2013) 
overnight at 4°C. Plates were washed with ELISA wash buffer (PBS, 0.05% Tween-20) and 
blocked with blocking buffer (PBS, 5% FBS) for 4 h at 37°C. Supernatants from B cell culture 
were added to the ELISA plates (50 µl per well) and processed as described above for serum 
antibodies. Positive wells were defined as wells that scored 2-fold over the mean OD of negative 
control wells (wells containing feeder cells and naïve B cells). The frequency of CHIKV-specific 
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MBCs was calculated as one cell per the number of cells plated where 63.2% of wells were 
positive. 
ELISpot assay. Mixed cellulose filter 96-well plates (Millipore) plates were pre-coated 
with 50 µg/ml of CHIKV E2 protein (Pal et al., 2013), 20 µg/ml of NP-CGG (Biosearch 
Technologies) or 2 µg/ml of H5 (Ellebedy et al., 2014) overnight at 4°C. After rinsing with 
ELISA wash buffer and PBS, plates were blocked for 4 h at 37°C with culture medium (RPMI, 
10% FBS, penicillin-streptomycin, 1mM sodium pyruvate, 0.1 mM non-essential amino acids, 
10 mM HEPES, and 50 µM β-mercaptoethanol). For LLPC assays, bone marrow from the tibia 
and femur was filtered through 40 µm cell strainer. For plasmablast assays, single cell splenocyte 
suspensions were generated as detailed above. Erythrocytes were lysed, and CD138+ cells were 
isolated using CD138 MicroBeads (130-098-257, Miltenyi Biotec). The isolated cells were 
incubated (RPMI 1640, 10% FBS, penicillin-streptomycin, 1 mM sodium pyruvate, 0.1 mM non-
essential amino acids, 10 mM HEPES, 50 µM β-mercaptoethanol) on the antigen-coated filter 
plates at 37°C and 5% humidified CO2 overnight, except for H5-specific plasmablasts which 
were incubated for 4 h. After washing with PBS, plates were incubated with 1% NP40 (Sigma) 
for 20 min at room temperature. Plates were washed with ELISA wash buffer and incubated 
sequentially with biotinylated anti-IgG (B7022, Sigma) and streptavidin-conjugated horseradish 
peroxidase (HRP; SA-5004, Vector Laboratories), each for 1 h at room temperature. After 
additional washes with PBS, substrate solution (5510-0050, SeraCare) was added. The reaction 
was quenched by washing with water. Spots were enumerated using a Biospot plate reader 
(Cellular Technology). 
Bone marrow transplantation. Four-week-old CD137-/- mice were irradiated with 900 
Rads and reconstituted via intravenous injection with 3 x 107 bone marrow cells isolated from 
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the femur and tibia of WT (CD45.1) or CD137-/- mice (CD45.2). After 8 weeks, immune cell 
reconstitution was confirmed by flow cytometry. 
Statistical analysis. All data were analyzed with GraphPad Prism software. For immune 
cell analysis, data were analyzed by the Mann-Whitney test or Kruskal-Wallis ANOVA with 
Dunn’s post-test. A Mann-Whitney test in lieu of an unpaired t test was used throughout for 
consistency, as some data did not show Gaussian distribution or had points at the level of 
detection. For serum antibody titer analysis, data were analyzed by two-way ANOVA with Sidak 










 Figure 3.1 Anti-CD137 mAb treatment reduces the number of GC B cells, antigen-
specific MBCs and LLPCs when given prior to GC formation. (A-G) Four-week-old WT 
C57BL/6 male mice were inoculated with 103 FFU of CHIKV. At 2 dpi, 400 mg of agonistic 
anti-CD137 or isotype control mAb was administered via an i.p. route. The number of total 
CD19+ B cells (B), PNA+CD95+ or GL7+CD95+ GC B cells (C-D) in the spleen at 7 and 14 dpi 
was analyzed by flow cytometry. (C) Representative dot plots of GC B cells are shown. At day 
90 dpi, spleen and bone marrow were harvested to assess antigen-specific MBCs (E) and LLPCs 
(F). (G) Serum was harvested at 7, 14, 30, 50, 65 and 90 dpi and anti-CHIKV IgG titers were 
measured. (H-J) Four-week-old WT C57BL/6 male mice were inoculated with 103 FFU of 
CHIKV. At 14 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb was administered 
via an i.p. route. The number of total CD19+ B cells (I) and PNA+CD95+ GC B cells (J) in the 
spleen at 28 dpi was analyzed by flow cytometry. (K-N) Four-week-old WT C57BL/6 male mice 
were inoculated with 103 FFU of CHIKV. At 56 dpi, 400 mg of agonistic anti-CD137 or isotype 
control mAb was administered via an i.p. route. At 90 dpi spleen and bone marrow were 
harvested to assess antigen-specific MBCs (L) and LLPCs (M). At this time, anti-CHIKV IgG 
titers (N) also were measured. (O) Four-week-old naïve WT C57BL/6 male mice were 
administered with 400 mg of agonistic anti-CD137 or isotype control mAb via an i.p. route. The 
numbers of PNA+CD95+ GC B cells in the spleen at 5 days after treatment were analyzed by 
flow cytometry. In this Figure, symbols represent individual mice, and bars indicate median 
values. Data are pooled from 2 to 4 experiments (Mann-Whitney test, except for serum antibody 
titers where two-way ANOVA with Sidak post-test was used: *, P < 0.05; **, P < 0.01; ***, P < 






 Figure 3.2. Anti-CD137 mAb treatment dampens T cell-dependent antibody 
responses. Four-week-old C57BL/6 male mice were injected via i.p. route with 5 µg of NP-KLH 
(A) or 10 µg of NP-Ficoll (F). At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb 
was administered via an i.p. route. (B-E) After immunization with NP-KLH, the number of 
PNA+CD95+ GC B cells (B) in the spleen at 14 days post-immunization was analyzed by flow 
cytometry. At day 130, bone marrow was harvested to profile antigen-specific LLPCs (C). At 30 
days post-immunization, antigen-specific MBCs were harvested from a separate set of animals 
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and profiled (D). Serum was collected at 7, 14, 21, 28, 35, 56, 76, 96 and 130 days post-
immunization, and anti-NP IgG (E) was measured. (G-J) After immunization with NP-Ficoll, 
bone marrow was harvested at day 130 to assess antigen-specific LLPCs (G). At 30 days post-
immunization, antigen-specific MBCs separately were harvested from a separate set of animals 
and profiled (H). Serum was collected at 7, 14, 21, 28, 35, 56 and 130 days post-immunization, 
and anti-NP IgM (I) and IgG (J) were measured. Symbols represent individual mice, and bars 
indicate median values, except for serum antibody titers where bars indicate mean values. Data 
are pooled from 3 experiments (Mann-Whitney test, except for serum antibody titers where two-
way ANOVA with Sidak post-test was used: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 






Figure 3.3. Anti-CD137 mAb treatment has a minimal effect on apoptosis and 
proliferation of GC B cells. Four-week-old WT C57BL/6 male mice were inoculated with 103 
FFU of CHIKV. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb was 
administered via an i.p. route. The number of CD86hiCXCR4low light zone B cells (A-B), and 
CD86hiCXCR4low dark zone B cells (A and C), and the percentage of annexin V+Viability Dye- 
early-stage apoptotic light zone and dark zone B cells (D-E; G, respectively), annexin 
V+Viability Dye+ late-stage apoptotic light and dark zone B cells (D and F; H, respectively), and 
Brdu+ proliferating light and dark zone B cells (I-J; K, respectively) in the spleen at 4, 5, 6 and 7 
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dpi was analyzed by flow cytometry. Representative dot plots of light and dark zone B cells (A), 
apoptotic light zone B cells (D), and proliferating light zone B cells (I) are shown. Symbols 
represent individual mice, and bars indicate median values, except for percentages where bars 
indicate mean values. Data are pooled from 3 experiments (Mann-Whitney test: *, P < 0.05; **, 








 Figure 3.4. Anti-CD137 mAb treatment has a minimal effect on the percentage of 
antigen-specific GC B cells. Four-week-old WT C57BL/6 male mice were inoculated with 103 
FFU of CHIKV. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb was 
administered via an i.p. route. (A-B) The percentage of CHIK VLP+ antigen-specific 
PNA+CD95+ GC B cells in the spleen at 4, 5, 6 and 7 dpi was analyzed by flow cytometry. (B) 
Representative flow cytometry dot plots of antigen-specific GC B cells are shown. Symbols 
represent individual mice, and bars indicate median values. Data are pooled from 2 experiments 







Figure 3.5. Anti-CD137 mAb results in a disorganization of B cell follicle 
architecture in the spleen. Four-week-old WT C57BL/6 male mice were inoculated with 103 
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FFU of CHIKV. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb was 
administered via an i.p. route. Spleens were harvested at 6 dpi (A-D), 7 dpi (E-F) and 14 dpi (I-
L) for imaging. (A-D) FDCs (green) were stained for CD21/35; IgD+ B cells (red), IgD; T cell 
zone (turquoise), CCL21. (B and D) Insets of the respective dotted boxes. (E-F) FDCs (green) 
were stained for CD21/35; IgD+ B cells (red), IgD; CD4+ T cells (snow), CD4. White scale bars 
indicate 50 mm. Yellow arrows indicate IgD+ B cells surrounding FDCs, and white arrows IgD+ 
B cells at the CCL21+ T cell zone border. (G-H) The number of CD21/35+CD54+ FDCs in the 
spleen at 7 and 14 dpi was analyzed by flow cytometry. (G) Representative flow cytometry dot 
plots of FDCs are shown. (I) B cells (blue) were stained for B220; FDCs (green), CD21/35; GC 
B cells (snow), GL7. White scale bars indicate 500 mm or 100 mm (insets). Each symbol 
represents individual FDC-containing follicle (J), GC B cell (K) or spleen (L), and bars indicate 
mean values. Quantification was done for: FDC area per FDC-containing-follicle (J), distance 
between the closest GC B cells (K), and GC B cells greater than 10 mm from an FDC (L). The 
images are representative of 3 spleens per group from 2 experiments (Mann-Whitney test: ***, P 







 Figure 3.6. Cell-intrinsic CD137 signaling in CD4+ or CD8+ T cells is required for 
anti-CD137 mAb-mediated inhibition of GC formation. Four-week-old (A) CD137-/- or (D) 
TCRβδ-/- mice were irradiated and then received bone marrow cells from WT or CD137-/- mice. 
After 8 weeks, recipient mice were inoculated with 103 FFU of CHIKV. At 2 dpi, 400 mg of 
agonistic anti-CD137 or isotype control mAb was administered via an i.p. route. (B) Immune cell 
reconstitution was confirmed in recipient mice. The number of PNA+CD95+ GC B cells (C, E 
and G) in the spleen at 14 dpi was determined. (F-G) Four-week-old TCRβδ-/- mice were 
administered 7.1 x 106 WT CD4+ T cells + WT CD8+ T cells, WT CD4+ T cells + CD137-/- CD8+ 
T cells, CD137-/- CD4+ T cells + WT CD8+ T cells or CD137-/- CD4+ T cells + CD137-/- CD8+ T 
cells via an i.v. route. Five days later, recipient mice were inoculated with 103 FFU of CHIKV. 
At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb was administered via an i.p. 
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route. Symbols represent individual mice, and bars indicate median values. Data are pooled from 






Figure 3.7. Immune cell populations identified by single cell RNA sequencing of 
splenocytes. Four-week-old WT C57BL/6 male mice were inoculated with 103 FFU of CHIKV. 
At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb was administered via an i.p. 
route. Single cell RNA sequencing was performed from spleens of naïve and CHIKV-infected 
mice at 3 and 7 dpi. Expression of CD3e (T cells), Ncr1 (NK cells), CD79a (B cells), Flt3 (DCs), 
Sdc1 (plasmablasts), Adgre1 (macrophages), S100a8 (neutrophils), Ccr2/Ly6c2 (monocytes) (A), 
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and Tnfrsf9 (B) is shown in tSNE plots. (C-D) Cell subsets among NK cells/T cells and B cells 







 Figure 3.8. Anti-CD137 mAb treatment increases the frequency of cycling CD8+ T 
cells with pro-inflammatory signatures. Four-week-old WT C57BL/6 male mice were 
inoculated with 103 FFU of CHIKV. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control 
mAb was administered via an i.p. route. Single cell RNA sequencing was performed from 
spleens of naïve mice and CHIKV-infected mice at 3 and 7 dpi. Cycling CD8+ T cells (Ccnb2, 
Ccna2, Cdca3 and Mki67; A) with pro-inflammatory signatures (Gzma, Gzmb and Ccl5; B) are 
shown in tSNE plots. (C) Expression of Gzmk in these cycling CD8+ T cells is shown in tSNE 








Figure 3.9. Anti-CD137 mAb treatment increases the frequency of neutrophils with 
pro-inflammatory signatures. Four-week-old WT C57BL/6 male mice were inoculated with 
103 FFU of CHIKV. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb was 
administered via an i.p. route. Single cell RNA sequencing was performed from spleens of naïve 
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mice and CHIKV-infected mice at 3 and 7 dpi. A subset of neutrophils (S100a8 and Mmp9; A-B) 
that expressed Ccrl2, Ccr1, Cxcr2 (C-D), Ly6i (E-F) and pro-inflammatory signatures (Cxcl2, 
Il1b, Ccl6, Csf1, Tnf, Tnfsf14 and Il15; G-H) is shown in tSNE plots. (I-J) Expression of Irg1 in 
this subset of neutrophils is shown in tSNE plots. B, D, F, H and J are insets of panel A, C, E, G 
and I, respectively, showing neutrophils at 7 dpi. Blue circled regions indicate neutrophils with 







 Figure 3.10. Anti-CD137 mAb treatment increases the frequency of differentiating 
monocytes with pro-inflammatory signatures. Four-week-old WT C57BL/6 male mice were 
inoculated with 103 FFU of CHIKV. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control 
mAb was administered via an i.p. route. Single cell RNA sequencing was performed from 
spleens of naïve mice and CHIKV-infected mice at 3 and 7 dpi. Monocytes (Ccr2 and Ly6c2; A), 
Spic-expressing differentiating monocytes (red circles) and red pulp macrophages (blue circles) 
(B-C) and reticulocytes (Hba-a1, Rhd and Tfrc; D) are shown in tSNE plots. Expression of pro-
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inflammatory signatures (Cxcl10, Cxcl9, Ccl2 and Cxcl16; E-F) and Ccr5 (G-H) in the 
differentiating monocytes is shown in tSNE plots. C, F and H are insets of panel B, E and G, 
respectively, showing differentiating monocytes at 3 dpi (C) or 7 dpi (F and H). Red circled 
regions indicate differentiating monocytes with pro-inflammatory signatures. Spleens from 3 







Figure 3.11. Anti-CD137 mAb treatment reduces the number of Tfh cells. Four-
week-old WT C57BL/6 male mice were inoculated with 103 FFU of CHIKV. At 2 dpi, 400 mg 
of agonistic anti-CD137 or isotype control mAb was administered via an i.p. route. (A) Single 
cell RNA sequencing was performed from spleens of naïve mice and CHIKV-infected mice at 3 
and 7 dpi. Expression of Tfh cell markers (Cxcr5 and Il21) in activated CD4+ T cells is shown in 
violin plots. (B-C) The number of CXCR5hiPD-1hi Tfh cells in the spleen at 7 dpi was analyzed 
by flow cytometry. (B) Representative flow cytometry dot plots of Tfh cells are shown. (D-E) At 
2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb in combination with anti-IL-2 
neutralizing or isotype (neutralizing) control mAb and anti-CTLA-4 blocking or isotype (block) 
control mAb was administered. IL-2 neutralizing and isotype (neutralizing) control mAb were 
administered again at 4 and 6 dpi. CTLA-4 blocking and isotype (blocking) control mAb were 
administered again at 5 dpi. Spleens were harvested at 7 dpi, and the number of CXCR5hiPD-1hi 
Tfh cells (D) and PNA+CD95+ GC B cells (E) was analyzed. Symbols represent individual mice, 
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and bars indicate median values. Data are pooled from 3 experiments (Mann-Whitney test for 
(C) and Kruskal-Wallis ANOVA with Dunn’s post-test for (D-E): *, P < 0.05; **, P < 0.01; ***, 








 Figure 3.12. Anti-CD137 mAb treatment increases the number of Tregs, Tfrs and 
CD8+FoxP3+ T cells. Four-week-old WT C57BL/6 male mice were inoculated with 103 FFU of 
CHIKV. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb was administered via 
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an i.p. route. (A-C) Single cell RNA sequencing was performed from spleens of naïve mice and 
CHIKV-infected mice at 3 and 7 dpi. (A) Tregs (Tnfrsf9, Foxp3, Il2ra and Tnfrsf18) are shown 
in tSNE plots. Expression of Foxp3 in activated CD4+ (B) and CD8+ T cells (C) is shown in 
violin plots. (D) Representative flow plots of CD137 expression on CD4+FoxP3+ Tregs and 
CD4+FoxP3- T cells from naïve CD137-/-, naïve WT or CHIKV-infected WT mice at 2 dpi are 
shown. The number and percentage of CD4+FoxP3+ Tregs (E-G), CD4+FoxP3+CXCR5hiPD-1hi 
Tfr cells (H-I) and CD8+FoxP3+ T cells (J-K) in the spleen at 7 dpi was analyzed by flow 
cytometry. (E) Representative flow plots of Tregs are shown. (L-N) Four-week-old TCRβδ-/- 
mice received FoxP3-GFP WT FoxP3+ T cells + CD137-/- T cells via i.v. route. After 5 days, the 
recipient mice were inoculated with 103 FFU of CHIKV. At 2 dpi, 400 mg of agonistic anti-
CD137 or isotype control mAb was administered via an i.p. route. (M) Reconstitution of Tregs 
and Tfr cells was confirmed in the recipient mice. (N) The number of PNA+CD95+ GC B cells in 
the spleen at 14 dpi was analyzed by flow cytometry. Symbols represent individual mice, and 
bars indicate median values, except for percentages where bars indicate mean values. Data are 








Figure 3.13. Anti-CD137 mAb treatment reduces the frequency of GC B cells. Four-
week-old WT C57BL/6 male mice were inoculated with 103 FFU of CHIKV. At 2 dpi, 400 mg 
of agonistic anti-CD137 or isotype control mAb was administered via an i.p. route. Single cell 
RNA sequencing was performed from spleens of naïve mice and CHIKV-infected mice at 3 and 
7 dpi. The tSNE plots show GC B precursors (Myc-activated pathway; A), cycling B cells (Cdc6, 
Cdc45, Cdc123, Cdc20, Cdc25b, Cdc37 and Mki67; B) expressing Ezh2 and Dnmt1 (C). B cell 
subset expressing GC B cell markers is shown in tSNE plots (S1pr2 and Aicda; D-E) and violin 
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plots (Mki67, Aicda, S1pr2 and Mef2b; F). (E) Insets of panel D (black boxes) showing cycling 
B cells at 7 dpi.  (G) Expression of Ccr7 in B cells is shown in tSNE plots. Spleens from 3 mice 











 Figure 3.14. Anti-CD137 mAb treatment reduces the number of MZ B cells and 
increases the number of plasmablasts. Four-week-old WT C57BL/6 male mice were 
inoculated with 103 FFU of CHIKV. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control 
mAb was administered via an i.p. route. (A) Single cell RNA sequencing was performed on 
spleens of naïve and CHIKV-infected mice at 3 and 7 dpi. Expression of Cd9, Cr2, Fcrl5 and 
Dtx1 in MZ B cells is shown in tSNE plots. (B) Expression of Dtx1 and Cr2 in MZ B cells is 
shown in violin plots. The number of CD21/35lowCD23hi follicular B cells (C-D) and 
CD21/35hiCD23low MZ B cells (C and E) in the spleen at 7 and 14 dpi was analyzed. (C) 
Representative flow cytometry dot plots of follicular and MZ B cells are shown. (F) The mean 
fluorescence intensity (MFI) of follicular and MZ B cells is shown. (G) Expression of Xbp1, Irf4 
and Prdm1 in plasmablasts is shown in tSNE plots. (H) The fraction of plasmablasts combined 
from all samples is shown in bar graphs. (I-J) The number of TACI+CD138+ plasmablasts in the 
spleen at 7 dpi was analyzed by flow cytometry. (I) Representative flow cytometry dot plots of 
plasmablasts are shown. (K) Four-week-old naive (uninfected) WT C57BL/6 male mice were 
administered 400 mg of agonistic anti-CD137 or isotype control mAb via an i.p. route. The 
numbers of TACI+CD138+ plasmablasts in the spleen at 5 days after treatment were analyzed by 
flow cytometry. (L) Four-week-old WT C57BL/6 male mice were inoculated with 103 FFU of 
CHIKV. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb was administered via 
an i.p. route. The number of antigen-specific plasmablasts in the spleen at 7 dpi was analyzed by 
ELISPOT. (M) Four-week-old WT C57BL/6 male mice were inoculated with 103 FFU of 
CHIKV. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb in combination with 
anti-CD40L blocking or isotype (block) control mAb was administered. Blocking and isotype 
(block) control mAb were administered again at 5 dpi. Spleens were harvested at 7 dpi, and the 
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number of TACI+CD138+ plasmablasts was analyzed by flow cytometry. (N) Immediately prior 
to CHIKV infection, IL-4-anti-IL-4 complex was administered via an i.p. route. IL-4-anti-IL-4 
complex was administered again at 1 and 2 dpi. At 2 dpi, 400 mg of agonistic anti-CD137 or 
isotype control mAb was administered via an i.p. route. Spleens were harvested at 7 dpi, and the 
number of plasmablasts was analyzed by flow cytometry. Symbols represent individual mice, 
and bars indicate median values, except for MFI where bars indicate mean values. Data are 
pooled from 3 experiments (Mann-Whitney test, except for (M-N) where Kruskal-Wallis 
ANOVA with Dunn’s post-test was used: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 







Figure 3.15. Anti-CD137 mAb treatment has a minimal effect on BCR usage or 
clonal expansion. Four-week-old WT C57BL/6 male mice were inoculated with 103 FFU of 
CHIKV. At 2 dpi, 400 mg of agonistic anti-CD137 or isotype control mAb was administered via 
an i.p. route. Single cell RNA sequencing was performed from spleens of naïve mice and 
CHIKV-infected mice at 3 and 7 dpi. V gene (A) and J gene (B) usage of heavy and light chains 
is shown. (C) The ball graph plots show heavy chain CDR3 clonality and extent of clonal 
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expansion with color-coded isotypes among plasmablasts. Each dot indicates a unique BCR 








 Figure 3.16. Effect of Anti-CD137 mAb treatment on antigen-specific B cell 
populations when administered before viral vaccine boosting. Nine-week-old WT C57BL/6J 
female mice were injected via an i.m. route with recombinant influenza A virus H5 
hemagglutinin proteins. 400 mg of agonistic anti-CD137 or isotype control mAb was 
administered via an i.p. route at either 2 days post-immunization (A) or 27 days post-
immunization (E) before secondary immunization with another dose of H5 at 28 days post-
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immunization. Spleens were harvested 7 days after the secondary booster immunization, and the 
numbers of GC B cells (B and F) and antigen-specific MBCs (C and G) were analyzed by flow 
cytometry. (D and H) The number of antigen-specific plasmablasts was analyzed by ELISPOT. 
Symbols represent individual mice, and bars indicate median values. Data are pooled from 2 





Chapter 4: Conclusion and Future Directions 
 
Reduced chikungunya infection by agonistic anti-CD137 monoclonal antibody 
B cell/FDC tropism of chikungunya virus 
The tropism of chronic CHIKV RNA in the musculoskeletal tissues and the lymphoid tissues is 
not clear, although there are some reports on the sites of viral replication during the acute phase 
of infection (Hawman et al., 2013; Nair et al., 2017; Young et al., 2019). Even though viral RNA 
was readily detected in the spleen, infectious virus was not recovered, as judged by plaque- or 
focus-forming assays. Nonetheless, higher E1/nsP2 RNA ratios were observed, consistent with 
productive infection. Based on the cell-sorting and tropism data in the spleen, GC B cells and 
FDCs were associated with the highest levels of viral RNA, on a per-cell basis, at 7 and 14 dpi. 
Unlike WT mice, neither µMT mice nor MD4 transgenic mice showed chronic viral RNA in 
their spleens, suggesting that the antigen-specific B cells are required for the persistence of 
CHIKV RNA in the spleen. It is plausible that B cells capture anti-CHIKV-antibody-CHIKV 
immune complex on their surface CRs and/or Fcγ receptors during the active process of antigen 
transportation to FDCs in the lymphoid follicles (Cinamon et al., 2008; Heinen et al., 1986). 
FDCs reportedly can retain HIV within nondegrative cycling compartments for long periods 
(Heesters et al., 2015). Similar phenomenon has not been reported for B cells. Although cell 
culture-adapted and some clinical isolates of CHIKV are dependent on glycosaminoglycans to 
differing extents for attachment and efficient infection, there has not been clear reports on 
receptors for CHIKV until recently when Zhang et. al. identified Mxra8 as an entry mediator for 
multiple arthritogenic alphaviruses, including CHIKV, using a genome-wide CRISPR-Cas9-
based screen (Silva et al., 2014; Zhang et al., 2018). Expression of Mxra8 on B cells has not been 
reported, and Raji, a B cell lymphoma cell line, does not express surface Mxra8 (Zhang et al., 
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2018). However, the possibility of other yet unidentified CHIKV receptor on B cells cannot be 
excluded. B cells can engage immune complex presented by FDCs, macrophages or DCs via 
BCR and internalize antigen-BCR complex, which is delivered to endocytic pathways. Whether 
CHIKV internalized through BCR contributes to chronic viral RNA is not clear. B cell tropism 
has been reported with PBMCs from dengue virus (DENV)-infected patients (King et al., 1999; 
Zanini et al., 2018). DENV may reside both on the surface and in intracellular compartments of 
B cells (King et al., 1999). Experiments involving protease digestion of splenic B cells from 
CHIKV-infected mice may provide insights into the localization of CHIKV RNA. Additionally, 
high-resolution imaging technique such as cryogenic electron microscopy may reveal some 
information on the location where viral RNA may reside. To test whether CHIKV-containing 
immune complexes binding to surface CR- or Fcγ receptors contribute to chronic viral RNA in 
the spleen, one could infect WT and CR- or Fcγ receptor-deficient mixed bone marrow chimeras 
with CHIKV and compare viral RNA contents between WT and the mutant cells. Additionally, 
virus-inactivated, CHIKV-immune serum could be adoptively transferred into µMT mice or 
MD4 transgenic mice before CHIKV infection. If the recipient animals show increased viral 
RNA in the spleens, the data would support the role of immune complex for chronic CHIKV 
RNA in the spleen. IgM dominates early antibody responses. The pentameric form of IgM 
efficiently activates complement upon binding to antigens and is trapped together with antigen 
on FDCs through the expressed CRs. Mice deficient in secreted IgM (sIgM-/-) show diminished 
antigen trapping on FDCs and germinal center reaction, suggesting the role of screted IgM for 
immune complex formation during early antibody responses (Boes et al., 1998). Since the B cells 
in sIgM-/- mice can still express antigen-specific, membrane-bound BCRs and produce IgG 
responses, if these mice do not show chronic CHIKV RNA in their spleens, the data would 
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support the model that CHIKV-containing immune complexes contribute to chronic viral RNA 
in the spleen.  
Agonistic anti-CD137 antibody-mediated viral clearance in lymphoid tissues 
While anti-CD137 mAb treatment induced clearance of CHIKV RNA in the lymphoid tissues, it 
minimally affected the levels of viral RNA in the feet of the same animals. The lack of CHIKV 
RNA clearance in the musculoskeletal tissues after anti-CD137 mAb treatment may be due to 
distinct viral tropism in these tissues (Nair et al., 2017; Young et al., 2019). The clearance of 
CHIKV RNA in the lymphoid tissues was correlated with a reduction in B cells and FDCs that 
was mediated by anti-CD137 mAb treatment and T cells. I hypothesize that anti-CD137 mAb 
clears CHIKV RNA in the lymphoid tissues by targeting B cells and/or FDCs, major reservoirs 
of chronic CHIKV RNA. Whether T cells eliminate viral RNA-containing cells in antigen-
specific manner is not clear. However, two sets of data do not support this scenario. Although the 
number of FDCs remained unchanged at 7 dpi, as judged by flow cytometry and 
immunofluorescence imaging, the levels of viral RNA in FDCs were significantly reduced after 
anti-CD137 mAb treatment at the same time point. Moreover, cell death analysis of germinal 
center B cells showed minimal difference in the frequencies of the cells undergoing apoptosis. 
Anti-CD137 mAb treatment reduced the surface expression of CRs on B cells, which may have 
resulted in less CHIKV-immune complexes binding to cells via CRs. This model would be 
supported if CR-deficient cells show decreased levels of CHIKV RNA compared to WT cells in 
the spleens of the CHIKV-infected mixed bone marrow chimera. It is possible that some chronic 
CHIKV RNA remains in intracellular compartments of B cells, which clear it after anti-CD137 
mAb treatment. This is supported by the scRNAseq analysis showing that the B cells in anti-
CD137 mAb-treated mice transcriptionally express higher levels of interferon stimulated genes 
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important in restricting CHIKV infection, such as Ifitm3 and Irf1, at 7 dpi compared to those in 
isotype control mAb-treated animals. 
Agonistic anti-CD137 antibody disrupts germinal center formation 
Altered B cell differentiation after anti-CD137 antibody treatment 
Anti-CD137 mAb treatment impaired GC formation and long-term antibody and B cell memory 
responses. Anti-CD137 mAb treatment did not enhance apoptosis or impair proliferation of B 
cells, nor did it significantly alter TI responses to NP-Ficoll. Although the number of Tfh was 
reduced after anti-CD137 mAb treatment, this effect could be due to decreased number of GC B 
cells as they are interdependent on each other. Boosting the number of Tfh using the combination 
of neutralizing anti-IL-2 and blocking anti-CTLA-4 antibodies did not restore the GC B cells. 
Whether or how the functions of Tfh are altered by anti-CD137 mAb treatment is not clear. 
scRNAseq analysis showed that anti-CD137 mAb treatment enhanced overall pro-inflammatory 
transcriptional program, including multiple cytokines, in T cells, neutrophils, and differentiating 
monocytes compared to isotype control mAb. Cytokines, including IFN-γ, IL-4, IL-10, IL-13, 
and IL-21, which regulate CSR and B cell maturation, signal through the activation of 
JAK/STAT pathways (Ding et al., 2013; Kiu and Nicholson, 2012). B cell-intrinsic IL-21 signals 
are required for optimal GC formation. In addition, IL-21 and CD40L synergistically promote 
plasma cell differentiation. This likely occurs through STAT3, activated by IL-21, and Irf4, 
activated by CD40L, competitively binding to shared Bcl6-binding sites within the regulatory 
sequences in Prdm1 gene and, therefore, increasing the expression of Prdm1, the transcription 
factor important for plasma cell differentiation (Ding et al., 2013; Kwon et al., 2009). IL-21 
signaling via STAT3 also sensitizes B cells to the stimulatory effects of IL-2 by inducing the 
expression of CD25, a component of IL-2 receptor (Berglund et al., 2013). IL-2-mediated 
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ERK/ELK1signaling pathway represses Bach2 and directs plasma cell lineage commitment 
(Hipp et al., 2017). Therefore, cytokines and their downstream STAT pathways are critical in B 
cell fate decisions and, if altered, may influence germinal center B cell differentiation. Adoptive 
transfer experiments showed that inhibition of GC formation required cell-intrinsic signaling of 
T cells. It is possible that anti-CD137 mAb-induced cytokines from T cells cause dysregulated 
differentiation of B cells. While the number of GC B cells was reduced in anti-CD137 mAb-
treated mice, the number of plasmablasts was increased compared to isotype control mAb-treated 
animals. Since repression of Bach2 and subsequent upregulation of Prdm1 directs plasma cell 
commitment, the cytokines produced by T cells in anti-CD137 mAb-treated mice may have 
inhibited the expression of Bach2. Ablation of Prdm1 restores GC differentiation of Bach2-
deficient B cells (Shinnakasu et al., 2016). If anti-CD137 mAb-mediated inhibition of GC was 
due to repression of Bach2, GC B cells should be restored in Prdm1-/- mice. 
Disrupted lymphoid follicle after anti-CD137 antibody treatment 
Anti-CD137 mAb-mediated inhibition of GC was correlated with changes in lymphoid follicle 
structure and GC B cell dispersal. By flow cytometry, the GC reaction seems normal until 7 dpi, 
when the numbers of both light and dark zone B cells were significantly reduced after anti-
CD137 mAb treatment. Thus, the early GC response may be minimally affected. Green et. al. 
described S1PR2, which is selectively expressed on GC B cells, as a GC confinement factor 
along with CXCR5 (Green et al., 2011). In S1PR2-/- immunized SRBCs, the boundary between 
the GC and mantle zone was less well defined, which was also seen in anti-CD137 mAb-treated 
mice (Green et al., 2011). However, the number of GC B cells was not altered in S1PR2-/- mice 
in contrast to the reduced number of GC B cells in anti-CD137 mAb-treated mice. It is possible 
that anti-CD137 mAb treatment induces decreased expression of S1PR2 on GC B cells or alters 
111	
	
the gradient of S1P, its ligand, produced by the stromal cells outside the follicles, which would 
result in dispersal of GC B cells, and additional factors contribute to their reduced number. This 
could be tested by measuring the expression of S1PR2 on GC B cells from anti-CD137 mAb-
treated mice and by performing migration assays in vitro. Additionally, B cells constitutively 
expressing S1PR2 could be adoptively transferred into anti-CD137 mAb- or isotype control 
mAb-treated, immunized mice. If the S1P gradient were not altered after anti-CD137 mAb 
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